

-EMBARGO-

The material contained in the attached document is under embargo, as it has not been approved by the Board of Directors of the American Academy of Pediatrics. It should not be made public under any circumstance. As a recipient of this document, you may review and comment on its content, but may not share, publish, post, broadcast, or distribute by any means its details before the embargo is lifted.

The embargo date for release to the public and press will be placed on the document following its approval by the AAP Board of Directors and acceptance for publication in Pediatrics.

-EMBARGO-

1 **Implementing the Key Action Statements of the American Academy of Pediatrics'**
2 **Attention-Deficit/Hyperactivity Disorder (ADHD) Clinical Practice Guidelines:**
3 **An Algorithm and Explanation for Process of Care for the Evaluation, Diagnosis,**
4 **Treatment, and Monitoring of ADHD in Children and Adolescents**

5
6 **I. INTRODUCTION**

7 **II. EVALUATION FOR ADHD**

8 II a. A Child or Adolescent Presents with Signs and Symptoms Suggesting ADHD
9 II b. Perform a Diagnostic Evaluation for ADHD and Evaluate or Screen for Comorbid
10 Disorders
11 II c. Gather Information From the Family
12 II d. Use Parent Rating Scales and Other Tools
13 II e. Gather Information from School and Community Informants
14 i. Teachers and Other School Personnel
15 ii. Academic Records
16 iii. Other Community Sources
17 II f. Gather Information From the Child or Adolescent
18 II g. Clinical Observations and Physical Examination of the Child or Adolescent
19 II h. Gather Information About Conditions That Mimic or are Comorbid With ADHD

20 **III. MAKING DIAGNOSTIC DECISIONS**

21 III a. DSM-5 Criteria for ADHD
22 III b. Developmental Considerations
23 i. Considerations About the Child or Adolescent's Age
24 ii. Considerations About the Child or Adolescent's Sex
25 III c. Consideration of Comorbid Conditions
26 i. Sleep Disorders
27 ii. Trauma
28 iii. Mental Health Conditions
29 iv. Learning Disabilities
30 v. Summary

31 **IV. TREATMENT**

32 IV a. Establish Management Team: Identify the Patient as a "Child With Special Health
33 Care Needs"
34 IV b. Establish Management Team: Collaborate With Family, School, and Child to
35 Identify Target Goals
36 IV c. Establish Management Team: Establish Team and Coordination Plan
37 i. Treatment Team
38 ii. Treatment Goals

iii. Management Plan

IV d. Treatment: Medication, Psychosocial Treatment, and Collaboration With the School to Enhance Support Services

i. Treatment: Medication

a. Follow-up Visits

ii. Treatment: Psychosocial Treatment

a. Behavioral Treatments

b. Training Interventions

c. Other Considerations

iii. Treatment: Collaborate With School to Enhance Support and Services

a. Educate Parents About School Services

V. AGE-RELATED ISSUES

V a. Preschool-Aged Children (Age 4 Years to the 6th Birthday)

V b. Adolescents (Age 12 Years to the 18th Birthday)

VI. MONITORING

VI a. Treatment Failure

VII. CHILDREN AND ADOLESCENTS FOR WHOM AN ADHD DIAGNOSIS IS NOT MADE

VII a. Other Condition

VII b. Apparently Typical or Developmental Variations

VII c. Children and Adolescents With Inattention or Hyperactivity/Impulsivity (Problem Level)

VIII. COMPLEMENTARY AND ALTERNATIVE THERAPIES/INTEGRATIVE MEDICINE

IX. IMPLEMENTATION ISSUES: PREPARING THE PRACTICE

X. CONCLUSION

I. INTRODUCTION

Practice guidelines provide a broad outline of the requirements for high-quality, evidence-based care. The American Academy of Pediatrics' (AAP) "Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents" provides the evidence-based processes for caring for children and adolescents with ADHD symptoms or diagnosis. This document supplements that guideline. It provides a process-of-care algorithm that details processes to implement the guidelines; describes procedures for the evaluation, treatment, and monitoring of children and adolescents with ADHD; and addresses practical issues related to the provision of ADHD-related care within a typical, busy pediatric practice. The algorithm is entirely congruent with the guidelines and is based on the practical experience and expert advice of clinicians who are experienced in the diagnosis and management of children and adolescents with ADHD. Unlike the guidelines, this algorithm is based primarily on expert opinion and has a less-robust evidence base because of the lack of clinical studies specifically addressing this approach. Understanding that providing appropriate care to children with ADHD in a primary care setting faces a number of challenges and barriers, the subcommittee has also provided an additional paper describing needed changes to address barriers to care (found in the supplemental files of this article online).

This algorithm describes a continuous process; as such, its constituent steps are not intended to be completed in a single office visit, or in a specific number of visits. Evaluation, treatment, and monitoring are ongoing processes, to be addressed throughout the

87 child/adolescent's care within the practice, and in transition planning as the adolescent moves
88 into the adult care system. Many factors will influence the pace of the process—including the
89 experience of the primary care clinician (PCC), the practice's volume, the longevity of the
90 relationship between the PCC and family, the severity of concerns, the availability of academic
91 records and school input, the family's schedule, and the payment structure.

92
93 An awareness of the AAP "Primary Care Approach to Mental Health Care Algorithm,"
94 which is available on the AAP Mental Health Initiatives website—will enhance the integration of
95 the procedures described in this document (<http://www.aap.org/mentalhealth>). That algorithm
96 describes the process to integrate an initial psychosocial assessment at well visits and a brief
97 mental health update at acute and chronic care visits. Mental health concerns, including
98 symptoms of inattention and impulsivity, may present when:

99

- Elicited during the initial psychosocial assessment at a routine well visit;
- Elicited during a brief mental health update at an acute or chronic visit; or
- Presented during a visit triggered by a family or school concern.


100
101
102
103 When concerns are identified, the algorithm describes the process of conducting a brief
104 primary care intervention, secondary screening, diagnostic assessment, treatment, and follow-up.
105 Like this document, the mental health algorithm is intended to present a process that may involve
106 more than one visit and may be completed over time.

107
108 This algorithm assumes that the primary care practice has adopted the initial psychosocial
109 assessment/mental health update, as described by the AAP [Mental Health Initiatives](#).¹ It begins
110 with steps paralleling the secondary assessment of the general mental health algorithm. Both
111 algorithms focus on the care team and include the family as a part of that team.

112
113 In light of the prevalence of ADHD, the severe consequences of untreated ADHD, and
114 the availability of effective ADHD treatments, the AAP recommends that *every* child/adolescent
115 identified with signs or symptoms suggestive of ADHD be evaluated for ADHD or other
116 conditions that may share its symptomatology. Documenting all aspects of the diagnostic and
117 treatment procedures in the patient's records will improve the ability of the pediatrician to best
118 treat children with ADHD.

119
120

ADHD Care Algorithm



121
122
123

II. EVALUATION FOR ADHD

1 Patients 4 years old to 18th birthday with signs or symptoms suggesting ADHD identified by parents' direct concerns or concerns from an initial psychosocial assessment.

See Task Force on Mental Health (TFOMH) Algorithms & ADHD Guideline Action Statement 1

124
125
126

II a. A Child or Adolescent Presents with Signs and Symptoms Suggesting ADHD

127

128 The algorithm's steps can be implemented when a child or adolescent presents to a PCC
 129 for an assessment for ADHD. This may occur in a variety of ways.

130

131 Pediatricians and other PCCs traditionally have longstanding relationships with the child
 132 and family, which foster the opportunity to identify concerns early on. The very young child may
 133 have a history of known ADHD risks, such as having parents who have been diagnosed with
 134 ADHD, or having extremely low birth weight. In those instances, the PCC would monitor for
 135 emerging issues.

136

137 Many parents bring their child/adolescent to the PCC with specific concerns about the
 138 child/adolescent's ability to sustain attention; curb activity levels; and/or inhibit impulsivity at
 139 home, school, or in the community. In many instances, the parents may express concerns about
 140 behaviors and characteristics that are associated with ADHD, but may not mention the core
 141 ADHD symptoms. For example, parents may report that their child is getting poor grades, does
 142 not perform well in team sports (despite being athletic), has very few friends, or is moody and
 143 quick to anger. These children and adolescents may have difficulty remaining organized;
 144 planning activities; or inhibiting their initial thoughts, actions, or emotions—behaviors that fall
 145 under the umbrella of executive functioning (ie, planning, prioritizing, and producing) or
 146 cognitive control. Problems with executive functions may be correlated with ADHD and are
 147 common among children and adolescents with ADHD. As recommended by *Bright Futures* (a
 148 national health promotion and prevention initiative led by the AAP²), routine psychosocial
 149 screening at preventive visits may identify concerns on the part of parent or another clinician.
 150 (See below for more information on co-occurring conditions.)

151

152 Finally, parents may bring a child to a PCC for ADHD evaluation based on the
 153 recommendation of a teacher, tutor, coach, etc.

154

155 (See the ADHD Guideline's Key Action Statement #1.)

156

157 II b. Perform a Diagnostic Evaluation for ADHD and Evaluate or Screen for Comorbid
158 Disorders

159

160

2 Perform Diagnostic Evaluation for ADHD and Evaluate or Screen for Other/Comorbid Conditions:		
See ADHD Guideline Action Statements 2-3		
<p>Family (parents, guardians, frequent caregivers):</p> <ul style="list-style-type: none"> ● Chief Concerns ● History of symptoms (e.g., age of onset & course) ● Family history including trauma & current acute stressors ● Past medical history ● Psychosocial history ● Review of systems ● Comorbid conditions ● Report of function (strengths & weaknesses) ● Validated ADHD instrument 	<p>School (and important community informants):</p> <ul style="list-style-type: none"> ● Concerns ● Comorbid conditions ● Report on patient's function in academic, work, and social interactions ● Academic records (e.g., report cards, standardized testing, psychoeducational evaluations) ● Administrative reports (e.g., disciplinary actions) ● Validated ADHD instrument 	<p>Child/adolescent (appropriate for child's age & development):</p> <ul style="list-style-type: none"> ● Interview, including concerns regarding behavior, family relationships, peers, school, anxiety and depression, abuse, trauma, bullying. ● Report of child's self-identified impression of function (strengths and weaknesses) ● Clinician's observations of child's behavior ● Physical and Neurological examination including fine & gross motor coordination ● For adolescents: Validated self-report instrument of ADHD and co-existing conditions

161

162

163

When a child or adolescent presents with concerns about ADHD, as described above, the clinician should initiate an evaluation for ADHD. (See the ADHD Guideline's Key Action

164 Statements #2 and #3.)

165

166 **II c. Gather Information From the Family**

167

168 As noted previously, the recommendations in the accompanying guideline are intended to
169 be integrated with the broader mental health algorithm developed as part of the AAP [Mental](#)
170 [Health Initiatives](#).^{1,3,4} It is also important for pediatricians and other PCCs to be aware of health
171 disparities and social determinants that may affect patient outcomes and to provide culturally
172 appropriate care to all children and adolescents in their practice, including during the initial
173 evaluation and assessment of the patient's condition.⁵⁻⁹

174

175 Ideally, the PCC's office staff obtains information from the family about the visit's
176 purpose at scheduling so that an extended visit or multiple visits can be made available for the
177 initial ADHD evaluation. This also increases the efficiency of an initial evaluation. Data on the
178 child/adolescent's symptoms and functioning can be gathered from parents, school personnel,
179 and other sources prior to the visit. Parents can be given rating scales that are to be completed
180 prior to the visit, by teachers, coaches, and others who interact with the child. This strategy
181 allows the PCC to focus on the most pertinent issues for that child/adolescent and family at the
182 time of the visit. (See later discussion for more information on rating scales.) Note that schools
183 will not release data to pediatric providers without written parental consent.

184

185 During the office evaluation session, the PCC reviews the patient's medical, family, and
186 psychosocial history. Developmental history is presumed to be part of the patient's medical
187 history. Family members (including parents, guardians and other frequent caregivers) are asked
188 to identify their chief concerns and provide a history of the onset, frequency, and duration of
189 problem behaviors; situations that increase or decrease the problems; previous treatments and
190 their results; and the caregivers' understanding of the issues. It is important to assess behaviors
191 and conditions that are frequent side effects of stimulant medication (ie, sleep difficulties, tics,
192 nail-biting, skin-picking, headaches, stomachaches, or afternoon irritability) and preexisting
193 conditions, so they are not confused with the frequent side effects of stimulants. This enables the
194 PCC to compare changes if medication is initiated later.

195

196 A sound assessment of symptoms and functioning in major areas can be used to construct
197 an educational and behavioral profile that *includes the child's strengths and talents*. Many
198 children with ADHD exhibit enthusiasm, exuberance, creativity, flexibility, the ability to detect
199 and quickly respond to subtle changes in the environment, a sense of humor, a desire to please,
200 etc. The most common areas of functioning affected by ADHD include academic achievement;
201 relationships with peers, parents, siblings, and adult authority figures; participation in
202 recreational activities, such as sports; and behavior and emotional regulation, including risky
203 behavior.

204

205 The *child and family's histories* can provide information about the status of symptoms
206 and functioning, and help determine age of onset and other factors that may be associated with
207 the presenting problems. It also identifies any potential traumatic events that the child may have
208 experienced, such as a family death, separation from the family, or physical or mental abuse.

209

210 The child/adolescent's *medical history* can help identify factors associated with ADHD,
211 such as prenatal and perinatal complications and exposures (eg, preterm delivery, maternal
212 hypertension, prenatal alcohol exposure), childhood exposures, and head trauma.

213
214 The *family history* includes any medical syndromes, developmental delays, cognitive
215 limitations, learning disabilities, trauma or toxic stress, or mental illness in the patient and family
216 members, including ADHD, mood, anxiety, and bipolar disorders. Ask what the family has
217 already tried, what works, and what does not work, to avoid wasting time on interventions that
218 have already been attempted unsuccessfully. Parental tobacco and substance use, including their
219 use prenatally, are relevant risk factors for, and correlate with, ADHD.¹⁰ ADHD is highly
220 heritable and is often seen in other family members, who may or may not have been formally
221 diagnosed with ADHD. For this reason, asking about family members' school experience—
222 including time and task management, grades, and highest grade level achieved—can aid in
223 treatment decisions.

224
225 The *psychosocial history* is important in any ADHD evaluation and usually includes queries
226 about environmental factors, such as family stress and problematic relationships, which
227 sometimes contribute to the child/adolescent's overall functioning. The caregivers' current and
228 past approaches to parenting and the child's misbehavior can provide important information that
229 may explain discrepancies between reporters. For example, parents may reduce their
230 expectations for their child with ADHD as a means to relieve parenting stress. When these
231 expectations are reduced (eg, eliminating chores, not monitoring homework completion, etc),
232 parents may experience far fewer problems with the child than do teachers, who may have
233 maintained expectations for the child to complete tasks and follow rules. Knowing the parents'
234 approach to parenting may help the PCC understand differences in ratings completed by parents
235 versus teachers.

236
237 Further evidence for an ADHD diagnosis includes an inability to independently complete
238 daily routines in an age-appropriate manner as well as multiple and short-lasting friendships;
239 trouble keeping and/or making friends; staying up late to complete assignments; and late,
240 incomplete, and/or lost assignments. Somatic symptoms and school avoidance are more common
241 among girls and may mask an ADHD diagnosis. With information obtained from the parents and
242 school personnel, the PCC can make a clinical judgment about the effect of the core—and
243 associated—ADHD symptoms on academic achievement, classroom performance, family and
244 social relationships, independent functioning, and safety/unintentional injuries.

245
246 If other issues exist, such as self-injuries, comorbid mental health issues also need to be
247 evaluated. Possible areas of functional impairment that require evaluation include domains such
248 as self-perception, leisure activities, and self-care (ie, bathing, toileting, dressing, and eating).
249 Additional guidance regarding functional assessment is available through the AAP ADHD
250 Toolkit³ and the AAP [Mental Health Initiatives](#).^{4,11} The ADHD Toolkit³ is being revised
251 concurrently with the development of these updated guidelines. Upon publication, the toolkit
252 may be accessed at: <https://www.aap.org/en-us/professional-resources/quality-improvement/Pages/Quality-Improvement-Implementation-Guide.aspx>. Additionally, a new
253 EQIPP Module was developed based on the new clinical recommendations and can also be
254 accessed using the same link above.
255

257 The patient needs to be screened for hearing and/or visual problems, because these can
258 mimic inattention. A full review of systems may reveal other symptoms or disorders, such as
259 sleep disturbances, absence seizures, or tic disorders, which may assist in formulating a
260 differential diagnosis and/or developing management plans. Internal feelings such as anxiety and
261 depression can occur but may not be noticeable to parents and teachers, so it is important to elicit
262 feedback about them from the patient as well.

263
264 The information gathered from this diagnostic interview, combined with the data from
265 the rating scales (see below), provides an excellent foundation for determining the presence of
266 symptoms and impairment criteria needed to diagnose ADHD.

267
268 **II d. Use Parent Rating Scales and Other Tools**

269
270 Rating scales that use the *Diagnostic and Statistical Manual of Mental Disorders, Fifth*
271 *Edition (DSM-5)* criteria for ADHD can help obtain the information that will contribute to
272 making a diagnosis. Rating scales for parents that use *DSM-5* criteria for ADHD are helpful in
273 obtaining the core symptoms required to make a diagnosis based on *DSM-5*.¹² Because changes
274 in the 18 core symptoms are essentially unchanged from *Diagnostic and Statistical Manual of*
275 *Mental Disorders, Fourth Edition (DSM-IV)* criteria, *DSM-IV*-based rating scales can be used if
276 *DSM-5* rating scales are not readily available. Some of these symptom rating scales include
277 symptoms of commonly comorbid conditions and measures of impairment in a variety of
278 domains that are also required for a diagnosis.^{13,14} Some available measures are limited, because
279 they provide only a global rating.^{15,16}

280
281 Caregiver and teacher endorsement of the requisite number of ADHD symptoms on the
282 rating scales is not sufficient for diagnosis. A rating scale documents the presence of inattention,
283 hyperactivity, and impulsivity symptoms, but not whether these symptoms are actually
284 attributable to ADHD versus a mimicking condition. Caregivers may misread or misunderstand
285 some of the behaviors. Furthermore, rating scales do not inform the PCC about contextual
286 influences that may account for the symptoms and impairment. Likewise, broadband rating
287 scales that assess general mental health functioning do not provide reliable and valid indications
288 of ADHD diagnoses, although they can help to screen for concurrent behavioral conditions.¹⁷

289
290 Nevertheless, parent ratings provide valuable information on their perspective of the
291 child's symptoms and impairment and add information about normative levels of the parents'
292 perspectives, which help the PCC determine the degree with which the problems are or are not in
293 the typical range for the child's age and sex. Finally, broad rating scales that assess general
294 mental health functioning do not provide sufficient information about all the ADHD core
295 symptoms but may help screen for the concurrent behavioral conditions.¹⁷

296
297 To address the rating scales' limitations, pediatricians and other PCCs need to interview
298 parents and may need to review documents such as report cards and results of standardized test
299 results and historical records of detentions, suspensions, and/or expulsions from school, which
300 can serve as evidence of functional impairment. Further evidence may include difficulty
301 developing and maintaining lasting friendships. This information is discussed below.

302
303 **II e. Gather Information from School and Community Informants**

305 Information from parents is not the only source that informs diagnostic decisions for
306 children and adolescents, because a key criterion for an ADHD diagnosis is the display of
307 symptoms and impairments in multiple settings. Gathering data from other adults who regularly
308 interact with the child or adolescent being evaluated provides rich additional information for the
309 evaluation.

310
311 The information from various sources may be inconsistent, because parents and teachers
312 observe the children at different times and under different circumstances, as described
313 previously.¹⁸ Disagreement may result from differences in students' behavior and performance in
314 different classrooms, their relationship with the teachers, or variations in teachers' expectations,
315 as well as training in or experience with behavior management. Classes with high homework
316 demands or classes with less structure are often the most problematic for students with ADHD.
317 Investigating these inconsistencies can lead to hypotheses about the child that help inform the
318 eventual clinical diagnoses and treatment decisions.¹⁹
319

320 *Teachers and Other School Personnel*

321
322 Teachers and other school personnel can provide critically important information as they
323 develop a rich sense of the typical range of behaviors within a specific age group over time.
324 School and classrooms settings provide the greatest social and performance expectations that
325 potentially tax children and adolescents with ADHD. Parents and older children may be the best
326 sources for identifying the school personnel who can best complete rating scales for an ADHD
327 evaluation.

328
329 The value of school ratings increases as children age, because parents often have less-
330 detailed information about their child's behavior and performance at school as the student moves
331 into the higher grades. With elementary and middle school children, the classroom teacher is
332 usually the best source; he or she may be the only source necessary. Other school staff, such as a
333 special education teacher or school counselor, may be valuable sources of information. Direct
334 communication with school psychologist and/or school counselor may provide additional
335 information on child's functioning within the context of the classroom and school.
336

337 In secondary schools, students interact with many teachers who often instruct more than
338 100 students daily. As a result, high school teachers may not know the students as well as
339 elementary and middle school teachers do. Parents and students may be encouraged to choose
340 the 2 or 3 teachers who they believe know the student best, and solicit their input (eg, math and
341 English teachers or, for children or adolescents with learning disabilities, a teacher in an area of
342 strong function and a teacher in an area of weak function). Regardless of the presence of a
343 learning disability, it is helpful to obtain feedback from the teacher of the class in which the child
344 or adolescent is having the most difficulty. The ADHD Toolkit provides materials relevant to
345 school data collection.
346

347 Teachers may communicate their major concerns using questionnaires or verbally in
348 person, via secure email (if available), or over the telephone. It is important to ask an appropriate
349 school representative to complete a validated ADHD instrument or behavior scale based on the
350 DSM-5 criteria for ADHD. A school representative's report might include information about any
351 comorbid or alternative conditions, including disruptive behavior disorders, depression and
352 anxiety disorders, tics, or learning disabilities. As noted, some parent rating scales have a version

353 for teachers, and assess symptoms and impairment in multiple domains.¹³ Teacher rating scales
354 exist that specifically target behavior and performance at school,²⁰ which provide a
355 comprehensive and detailed description of a student's school functioning relative to normative
356 data.

357

358 In addition to the academic information, it is important to request information
359 characterizing the child/adolescent's level of functioning with regards to peer, teacher, and other
360 authority figure relationships; ability to follow directions; organizational skills; history of
361 classroom disruption; and assignment completion.

362

363 *Academic Records*

364

365 In addition to ratings from teachers and other school staff, academic records are
366 sometimes available to inform a PCC's evaluation. These records include report cards; results
367 from reading, math, and written expression standardized tests; and other assessments of
368 academic competencies. If a child was referred for an evaluation for special education services,
369 his or her file is likely to contain a report on the evaluation, which can be very useful during an
370 ADHD evaluation. School records pertaining to office discipline referrals, suspensions, absences,
371 and detentions can provide valuable information about social function and behavioral regulation.
372 Parents often keep report cards from early grades, which can provide valuable information about
373 age of onset for children older than 12 years. Teachers in primary grades often provide
374 information pertaining to important information about the history of the presenting problems.

375

376 *Other Community Sources*

377

378 It can be helpful to obtain information not only from school professionals but also from
379 additional sources, such as grandparents, faith-based organization group leaders, scouting
380 leaders, sports coaches, and others. Depending on the areas in which the child or adolescent
381 exhibits impairment, these adults may be able to provide a valuable perspective on the nature of
382 the presenting problems, although the accuracy of their reporting has not been studied.

383

384 II f. Gather Information From the Child or Adolescent

385

386 Another source of information is the child or adolescent himself or herself. This
387 information is often collected, but carries less weight than information from other sources
388 because of children's and adolescents' limited ability to accurately report their strengths and
389 weaknesses—including those associated with ADHD.²¹ As a result, information gathered from
390 the child about specific ADHD behaviors may do little to inform the presence or absence of
391 symptoms and impairments, as evidence suggests that children tend to minimize their problems
392 and blame others for concerns.²²

393

394 Nevertheless, self-report may provide other values. First, self-report is the primary means
395 by which one can screen for internalizing conditions such as depression and anxiety. The AAP
396 Mental Health Initiatives⁴ and the *Guidelines for Adolescent Depression in Primary Care*
397 (*GLAD-PC*)²³⁻²⁵ recommend the use of validated diagnostic rating scales for adolescent mood
398 and anxiety disorders for clinicians who wish to use this format.²⁶⁻³⁰ As measures of internal
399 mental disorders, these data are likely to be more valid than the reports of adults about their
400 children's behaviors.

401
402 Second, youth with ADHD are prone to talk impulsively and excessively when adults
403 show an interest in them. They may share useful information about the home or classroom that
404 parents and teachers do not know or impart. In addition, many share their experience with risky
405 and dangerous behaviors that may be unknown to the adults in their lives. This information can
406 be critical in both determining a diagnosis and designing treatment.

407
408 Third, even if little information of value is obtained, the fact that the PCC takes the time
409 to meet alone and ask questions of the child or adolescents demonstrates respect and lays the
410 foundation for collaboration in the decision-making and treatment process to follow. This
411 relationship building is particularly important for adolescents.

412
413 Fourth, by gaining an understanding of the child's perspective, the PCC can anticipate the
414 likely acceptance or resistance to treatment.

415
416 Interviewing the child or adolescent provides many important benefits beyond the
417 possibility of informing the diagnosis and warrants its inclusion in the evaluation. For example,
418 part of this interview includes asking the child or adolescent to identify personal goals (for
419 example, what do you want to be when you grow up? What do you think that requires? How can
420 we help you get there?). It is helpful when children perceive the pediatrician and other PCCs as
421 seeking to help them achieve their goals rather than arbitrarily labeling them as deficient,
422 defective, or needing to be fixed in some way.

423
424 **II g. Clinical Observations and Physical Examination of the Child or Adolescent**

425
426 The physical and neurologic examination needs to be comprehensive to determine
427 whether further medical or developmental assessments are indicated. Baseline height, weight,
428 blood pressure, and pulse measurements are required to be recorded in the medical record. It is
429 important to look for behaviors that are consistent with ADHD's symptoms—including the
430 child's level of attention, activity, and impulsivity during the encounter. Yet, ADHD is context
431 dependent, and for this reason, behaviors and core symptoms that are seen in other settings are
432 often not observed during an office visit.³¹ Although the presence of hyperactivity and
433 inattention during an office visit may provide supporting evidence of ADHD symptoms, their
434 absence is not considered evidence that the child does not have ADHD.

435
436 Observations of a broad range of behaviors can be important for considering their
437 contribution to the presenting problems and the potential diagnosis of other conditions. Careful
438 attention to these various behaviors can provide useful information when beginning the next step
439 involving making diagnostic decisions. For example, hearing and visual acuity problems can
440 often lead to inattention and overactivity at school. Attending to concerns about anxiety is also
441 important, given that young children may become overactive when they are in anxiety-provoking
442 situations like a clinic visit.

443
444 In addition, observing the child's language skills is important, because difficulties with
445 language can be a symptom of a language disorder and predictor of subsequent reading
446 problems. This observation is particularly important with very young children, given that
447 language disorders may present as problems with sustaining attention and impulsivity. A
448 language disorder may also involve pragmatic usage or the social use of language, which can

449 contribute to social impairment. If the PCC, family, and/or school have concerns about receptive,
450 expressive, or pragmatic language, it is important to make a referral for a formal speech and
451 language evaluation. Dysmorphic features also need to be noted, because symptoms of ADHD
452 are similar to characteristics of children with some prenatal exposures and genetic syndromes
453 (eg, fetal alcohol exposure,^{32,33} fragile X syndrome).

454

455 Many children with ADHD have poor coordination, which may be severe enough to
456 warrant a diagnosis of developmental coordination disorder and referral to occupational and/or
457 physical therapy. Findings of poor coordination can affect how well the child performs in
458 competitive sports, a frequent source of social interactions for children, and can adversely affect
459 the child's writing skills. Detecting any motor or verbal tics is important as well, particularly
460 because the use of stimulant medications may cause or exacerbate tics.

461

462 Finally, it is important to evaluate the child's cardiovascular status, because
463 cardiovascular health must be considered if ADHD medication becomes an option. Cardiac
464 illness is very rare, and more evidence is required to determine whether children or adolescents
465 with ADHD are at increased risk when taking ADHD medications. Nevertheless, before
466 initiating therapy with stimulant medications, it is important to obtain the child or adolescent's
467 history of specific cardiac symptoms, as well as the family history of sudden death,
468 cardiovascular symptoms, Wolf-Parkinson-White syndrome, hypertrophic cardiomyopathy, and
469 long QT syndrome. If any of these risk factors are present, clinicians should obtain additional
470 evaluation with an electrocardiogram (EKG) and possibly consult with a pediatric cardiologist.

471

472 **II h. Gather Information About Conditions That Mimic or are Comorbid With ADHD**

473 It is important for the PCC to obtain information about the status and history of
474 conditions that may mimic or are comorbid with ADHD, such as depression, anxiety disorders,
475 and post-traumatic stress disorder. Several validated rating scales are within the public domain
476 and can help identify comorbid conditions. Examples include the Pediatric Symptom Checklist-
477 17 (PSC-17) as a screen for depression and anxiety³⁴; the Screen for Child Anxiety Related
478 Emotional Disorders (SCARED), more specifically for anxiety disorders²⁸; and the Patient
479 Health Questionnaire modified for adolescents (PHQ-A), the Screening to Brief Intervention
480 (S2BI) tool^{35,36}; and the Child and Adolescent Trauma Screen (CATS) for exposure to trauma.³⁷
481 All include questionnaire forms for both parents and patients.³ The results help the PCC assess
482 the extent to which reported impairment and/or distress are associated with ADHD versus
483 comorbid conditions. These conditions are described in greater detail later.


484

485 *Safety and serious mental illness concerns:* PCCs may be asked to complete mental
486 health or safety assessments, particularly for adolescents. Assessment requests may come from
487 schools or other settings after a behavioral crisis, aggressive behavior, or destructive behaviors
488 have occurred. With patient or guardian consent, information may be shared regarding diagnosis
489 and current treatment strategies. Pediatricians and other PCCs are encouraged to exercise caution
490 when asked to predict the likelihood of future behaviors in the absence of detailed understanding
491 of the environment in which the behaviors occurred. *Self-injurious behaviors or threats of self-*
492 *harm are serious concerns that, when possible, should immediately be referred to community*
493 *mental health crisis services or experienced child mental health professionals. PCCs are*
494 *encouraged to provide further monitoring of the child or adolescent with these comorbidities.*

495

496 **III. MAKING DIAGNOSTIC DECISIONS**

497



498

499

500 After gathering all of the relevant available information, the PCC will consider an ADHD
501 diagnosis as well as a diagnosis of other related and/or comorbid disorders. The primary
502 decision-making process involves comparing the information obtained to the *DSM-5* criteria for
503 ADHD. Although this assessment is straightforward, there are some issues the PCC needs to
504 consider, including development, sex, and other disorders that may fit the presenting problems
505 better than ADHD (see below for more on these issues).

506

507 **III a. DSM-5 Criteria for ADHD**

508

509 The *DSM-5* criteria define 4 dimensions of ADHD:

510 1. ADHD primarily of the *Inattentive* presentation (ADHD/I) (314.00 [F90.0]);
511 2. ADHD primarily of the *Hyperactive-Impulsive* presentation (ADHD/HI) (314.01 [F90.1]);
512 and
513 3. ADHD *Combined* presentation (ADHD/C (314.01 [F90.2]).
514 4. ADHD *Other Specified*, and *Unspecified* ADHD (314.01 [F90.8])

515

516 To make a diagnosis of ADHD, the PCC needs to establish that **6** or more (5 or more if
517 the adolescent is 17 years or older) core symptoms are present in either or both of the
518 “Inattention Dimension” and/or the “Hyperactivity-Impulsivity Dimension” and occur
519 inappropriately often. The core symptoms and dimensions are presented in **Table 1**, below.

520 • ADHD/I: having at least 6 of 9 *Inattention* behaviors, and less than 6 *Hyperactive-Impulsive*
521 behaviors.

522 • ADHD/HI: having at least 6 of 9 *Hyperactive-Impulsive* behaviors, and less than 6
523 *Inattention* behaviors.

524 • ADHD/C: having at least 6 of 9 behaviors in both the *Inattention* and *Hyperactive-Impulsive*
525 dimensions.

526 • *ADHD Other Specified*, and *Unspecified ADHD*: These categories are meant for children
527 who meet many of the criteria, for ADHD, but not the full criteria, and who have significant
528 impairment. “ADHD Other Specified” is used if the PCC specifies those criteria that have
529 not been met; “Unspecified ADHD” is used if the PCC does not specify these criteria.

530

531

Table 1. Core Symptoms of ADHD From the DSM-5

Inattention Dimension	Hyperactivity-Impulsivity Dimension	
	Hyperactivity	Impulsivity
<ul style="list-style-type: none">▪ Careless mistakes▪ Difficulty sustaining attention▪ Seems not to listen▪ Fails to finish tasks▪ Difficulty organizing	<ul style="list-style-type: none">▪ Fidgeting▪ Unable to stay seated▪ Moving excessively (restless)▪ Difficulty engaging in leisure activities quietly	<ul style="list-style-type: none">▪ Blurt answers before questions completed▪ Difficulty awaiting turn

573 In the absence of other concerns and findings on prenatal or medical history, further
574 diagnostic testing will not help to reach an ADHD diagnosis. Compared with clinical interviews,
575 standardized psychological tests, such as computerized attention tests, have not been found to
576 reliably differentiate between youth with and without ADHD.^{41,42} Appropriate further assessment
577 is indicated, if an underlying etiology is suspected. Imaging studies or screening for high lead
578 levels and abnormal thyroid hormone levels can be pursued if they are suggested by other
579 historic or physical information, such as history or symptoms of a tumor or significant brain
580 injury. When children experience trauma, their evaluation needs to include the consideration of
581 both the trauma and ADHD, because they can co-occur and can exacerbate ADHD symptoms.
582 Toxic stress has shown to be associated with the incidence of pediatric ADHD, but the
583 conclusion that ADHD is a manifestation of this stress has not been demonstrated.⁴³

584
585 Patients with ADHD commonly have comorbid conditions, such as oppositional defiant
586 disorder, anxiety, depression, and language and learning disabilities. These conditions may
587 present with ADHD symptoms and need evaluation, because their treatment may relieve
588 symptoms. Additionally, some conditions may present with ADHD symptoms and respond to
589 treatment of the primary condition, such as sleep disorders, absence seizures, and
590 hyperthyroidism. (Comorbid conditions are discussed later in this document.)

591
592 In addition, the behavioral characteristics specified in the *DSM-5* remain subjective and
593 may be interpreted differently by various observers. Rates of ADHD and its treatment have been
594 found to be different for different racial/ethnic groups.^{44,45} Cultural norms and the expectations
595 of parents or teachers may influence reporting of symptoms. Hence, the clinician benefits from
596 being sensitive to cultural differences about the appropriateness of behaviors and perceptions of
597 mental health conditions.^{7,8}

598
599 After the diagnostic evaluation, a PCC will be able to answer the following questions:
600 • How many inattentive and hyperactive/impulsive behavior criteria for ADHD does the
601 child/adolescent manifest across major settings of his or her life?
602 • Have these criteria been present for 6 months or longer?
603 • Was the onset of these or similar behaviors present before the child's 12th birthday?
604 • What functional impairments are caused by these behaviors?
605 • Could any other condition be a better explanation for the behaviors?
606 • Is there evidence of comorbid problems or disorders?

607
608 On the basis of this information, the clinician is usually able to arrive at a preliminary
609 diagnosis of whether the child or adolescents has ADHD or not. (For children and adolescents
610 who do not receive an ADHD diagnosis, see below.)

611
612 **III b. Developmental Considerations**

613
614 ***Considerations About the Child or Adolescent's Age***

615
616 Although the diagnostic criteria for ADHD are the same for children up to age 17 years,
617 developmental considerations affect the interpretation of whether a symptom is present. Prior to
618 school age, the primary set of distinguishing symptoms involve hyperactivity—although this can
619 be difficult to identify as outside of the normal range given the large variability in this young age

620 group. Similarly, difficulties sustaining attention are difficult to determine with young children
621 because of considerable variability in presentation and the limited demands for children in this
622 age group to sustain attention over time. (See below for more information on developmental
623 delays.)

624

625 Some children demonstrate hyperactivity and inattention that are clearly beyond the
626 normal range. They may experience substantial impairment to an extent that babysitters or child
627 care agencies refuse to care for them, parents are unable to take them shopping or to restaurants,
628 or they routinely engage in dangerous or risky behaviors. In these extreme cases, the PCC may
629 be able to make the decision for an ADHD diagnosis more quickly than other scenarios that
630 require a thorough assessment. For other young children, the diagnosis will be less obvious, and
631 developmental and environmental issues may lead the PCC to be cautious in making an ADHD
632 diagnosis. In these situations, monitoring for the emergence or clarification of ADHD symptoms
633 and/or providing a diagnosis of *Other Specified ADHD* or *Unspecified ADHD* are appropriate
634 options.

635

636 Adolescence is another developmental period when developmental considerations are
637 warranted. Beginning at age 17 years, there are only 5 symptoms of inattention and/or 5
638 symptoms of hyperactivity/impulsivity required for an ADHD diagnosis. Hyperactivity typically
639 diminishes for most children during adolescence, but problems associated with impulsivity can
640 be dangerous and can include impaired driving, substance use, risky sexual behavior, and
641 suicide. Disorganization of time and resources can be associated with substantial academic
642 problems at school. Parent-child conflict and disengagement from school can provide a context
643 that contributes toward poor long-term outcomes. Comorbid depression and conduct disorder are
644 common but do not negate the importance of diagnosing ADHD when the developmental path
645 warrants it and the ADHD symptoms exacerbate problems associated with the comorbid
646 conditions.

647

648 Adolescence is the first developmental period for which age of onset of symptoms must
649 be documented prior to 12 years. School records and parent reports are often the richest source
650 for making this determination. It is important to try to identify adolescents (or their parents) who
651 are pursuing a diagnosis of ADHD for secondary gains such as school accommodations,
652 standardized testing accommodations, and/or stimulant prescriptions. In addition, impairment
653 sometimes emerges when expectations for the adolescent markedly increase or when
654 accommodations are removed. The teenager's level of functioning may stay the same, but when
655 faced with the expectations of advanced placement courses or a part-time job, failure to keep
656 pace with increasing expectations may lead to concerns that warrant an evaluation for ADHD.
657 These examples emphasize the importance of determining an early age of onset.

658

659 *Considerations About the Child or Adolescent's Sex*

660

661 ADHD is diagnosed in boys about twice as often as it is diagnosed in girls. There are
662 many hypotheses about reasons for this difference; the primary reason appears to simply be that
663 the disorder is more common in boys than girls. Some have raised concerns that the difference
664 may be attributable to variances in society's expectations for boys versus girls or underdiagnosis
665 in girls, but these reasons are unlikely to account for the large difference in diagnoses. Hence, no
666 adjustment is needed in terms of the standards for girls to meet the criteria for an ADHD
667 diagnosis compared with boys.

668
669
670
671
672
673


Girls are less likely to exhibit hyperactivity symptoms, which are the most easily observable of all ADHD symptoms, particularly in younger patients. This fact may account for a portion of the difference in diagnosis between girls and boys. As a result, it is important to fully consider a diagnosis of ADHD, predominantly inattentive presentation, when evaluating girls.

674
675
676
677
678
679
680
681
682

Symptoms of inattention alone can complicate the diagnosis, because inattention is one of the most common symptoms across all disorders in *DSM-5*. After puberty, it is more common for depression and anxiety to be diagnosed in girls than in boys, and symptoms of inattention may be a result of these disorders as well as ADHD. Examining the age of onset and considering other distinguishing features, such as avoidance and anhedonia, can help the PCC clarify this challenging differential when evaluating girls for ADHD. For example, does the inattention occur primarily in anxiety-provoking situations or when the child or adolescent is experiencing periods of low mood, and then remit when the anxiety or mood improves?

683
684

III c. Consideration of Comorbid Conditions



685
686

If other disorders are suspected or detected during the diagnostic evaluation, an assessment of the urgency of these conditions and their impact on the ADHD treatment plan should be made. Comorbid conditions provide unique challenges for treatment planning. *Urgent conditions need to be addressed immediately with services capable of handling crisis situations. These conditions include suicidal thoughts or acts and other behaviors with the potential to severely injure the child, adolescent, and/or other people, including severe temper outbursts or child abuse.* Note that adolescents are potentially more likely to provide honest answers if the PCC asks sensitive questions in the absence of the parents and may respond more readily to rating scales that assess mood or anxiety. In addition, substance use disorders require *immediate* attention and may precede or coincide with beginning treatment for ADHD. Additional information is available in the complex ADHD guideline published by the Society for Developmental and Behavioral Pediatrics (SDBP).⁴⁶

699

700 Evidence shows that comorbid conditions may improve with treatment of ADHD,
701 including oppositional behaviors and anxiety.⁴⁷ For example, children with ADHD and comorbid
702 anxiety disorders may find that addressing the ADHD symptoms with medications also decreases
703 anxiety or mood symptoms. Other children may require additional therapeutic treatments to treat
704 the ADHD adequately and treat comorbid conditions, including cognitive behavioral therapy
705 (CBT), academic interventions, or different and/or additional medications.

706

707 The PCC may evaluate and treat the comorbid disorder if it is within his or her training
708 and expertise. In addition, the PCC can provide education to family and child or adolescent about
709 triggers for inattention and/or hyperactivity. If the PCC requires the advice of a subspecialist, the
710 clinician is encouraged to consider carefully when to initiate treatment for ADHD. In some
711 cases, it may be advisable to delay the start of medication until the role of each member of the
712 treatment team is established (see below). Integrated care models can be helpful (see
713 www.integratedcareforkids.org).

714

715 Following are brief discussions of sleep disorders, psychiatric disorders, emotion
716 dysregulation, exposure to trauma, and learning disabilities—all of which can manifest in
717 manners similar to ADHD and can complicate making a diagnosis.

718

719 (See ADHD Guideline's Key Action Statement #3.)

720

721 *Sleep Disorders*

722

723 Sleepiness impairs most people's ability to sustain attention and often leads to caffeine
724 consumption to counter these effects. In the same way, sleep disturbance can lead to symptoms
725 and impairment that mimic or exacerbate ADHD symptoms. A child with ADHD may have
726 difficulty falling asleep because of the busy thoughts caused by ADHD. Some sleep disorders are
727 frequently associated with ADHD or present as symptoms of inattention, hyperactivity, and
728 impulsivity, such as obstructive sleep apnea syndrome (OSAS) and restless legs
729 syndrome/periodic limb movement disorder (RLS/PLMD).⁴⁸⁻⁵¹

730

731 The differential diagnosis of insomnia in children and adolescents with ADHD includes:

- 732 • *Inadequate sleep hygiene* (eg, inconsistent bedtimes and wake times, absence of a bedtime
733 routine, electronics in the bedroom, caffeine use).⁵²
- 734 • *ADHD medication* (stimulant and nonstimulant) effects:
 - 735 ○ Direct effects on sleep architecture: prolonged sleep onset, latency, and decreased
736 sleep duration, increased night wakings.⁵³⁻⁵⁵
 - 737 ○ Indirect effects: inadequate control of ADHD symptoms in the evening, and
738 medication withdrawal or rebound symptoms.^{56,57}
- 739 • *Sleep problems associated with comorbid psychiatric conditions* (eg, anxiety and mood
740 disorders, disruptive behavior disorders).⁵⁸
- 741 • *Circadian-based phase delay in sleep-wake patterns*, which have been shown to occur in
742 some children with ADHD, resulting in both prolonged sleep onset and difficulty waking in
743 the morning.⁵⁹
- 744 • *Intrinsic deficit associated with ADHD*. Numerous studies have reported that nonmedicated
745 children with ADHD without comorbid mood or anxiety disorders have significantly greater

746 bedtime resistance, more sleep onset difficulties, and more frequent night awakenings when
747 compared with typically developing controls.⁶⁰ In addition, some children with ADHD
748 appear to have evidence of increased daytime sleepiness, even in the absence of a primary
749 sleep disorder.⁶⁰⁻⁶²

750
751 For this reason, *all* children and adolescents who are evaluated for ADHD need to be
752 systematically screened for symptoms of primary sleep disorders, such as frequent snoring,
753 observed breathing pauses, restless sleep, urge to move one's legs at night, and excessive
754 daytime sleepiness. (Issues of access to these services are discussed in the accompanying
755 supplemental paper "Systemic Barriers to the Care of Children and Adolescents with ADHD.")
756 In addition, screenings generally include primary sleep disorders' risk factors, such as
757 adenotonsillar hypertrophy, asthma and allergies, obesity, a family history of RLS/PLMD, and
758 iron deficiency.⁵⁷ Sleep assessment measures that have been shown to be useful in the pediatric
759 primary care practice setting include brief screening tools⁶³ and parent-report surveys.^{64,65}
760 Overnight polysomnography is generally required for children who have symptoms suggestive of
761 and/or risk factors for OSAS and RLS/PLMD.^{66,67}

762
763 If the results suggest the presence of a sleep disorder, the PCC needs to obtain a
764 comprehensive sleep history, including assessment of the environment where the child sleeps,
765 the cohabitants in the room; the bedtime routine, including its initiation, how long it takes for the
766 child fall asleep, sleep duration, and any night-time awakenings; and what time the child wakes
767 up in the morning, and his/her state when awakening. It is important to determine sleep
768 interventions attempted and their results. Even when no primary sleep disorders occur, modest
769 reductions in sleep duration or increases in sleep disruption may be associated with increased,
770 detectable problems with attention in children and adolescents with ADHD.⁶⁸ Although fully
771 disentangling sleep disruption from ADHD may not be possible because significant sleep
772 problems and their associated impairment are often comorbid with ADHD, sleep disruptions
773 often warrant consideration as an additional target for treatment. In addition, some children with
774 ADHD appear to show evidence of increased daytime sleepiness, even in the absence of a
775 primary sleep disorder.^{61,62} Significant sleep problems and their associated impairment are often
776 comorbid with ADHD and, for many children, are considered as an additional target for
777 treatment.

778
779 A variety of issues need to be considered when determining whether sleep problems
780 constitute an additional diagnosis of insomnia disorder or are linked to ADHD-related treatment
781 issues. First, a child's sleep can be affected if he or she is already taking stimulant medication or
782 regularly consuming caffeine. The dosage and timing of this consumption needs to be tracked
783 and manipulated to examine its effects; simple modifications of timing and dosage of stimulant
784 consumption can improve sleep onset, duration, and quality. Second, sleep problems can occur
785 from inadequate sleep health/hygiene⁵² or from other disorders, such as anxiety and mood
786 disorders, when the rumination and worry associated with them impairs or disrupts the child's
787 sleep. Restructuring behavior preceding and at bedtime can dramatically improve sleep and
788 diminish associated impairments. These potential causes of sleep disturbance and the related
789 impairments that mimic or exacerbate ADHD symptoms need to be considered before
790 diagnosing ADHD, related problems, or insomnia disorder.

791
792 *Trauma*

793

794 Children with ADHD are at higher-than-normal risk of experiencing some forms of
795 trauma including corporal punishment and accidents (often because of their risk-taking
796 behaviors). In addition, post-traumatic stress disorder may manifest some similar symptoms.
797 Depending on the child, the trauma may have been a one-time event or one to which they are
798 consistently exposed. Exposure to trauma may exacerbate or lead to symptoms shared by trauma
799 disorders and ADHD (eg, inattention). As a result, when evaluating a child for ADHD, obtaining
800 a brief trauma history and screening for indicators of impairing responses to trauma can be
801 helpful. Although a trauma history does not inform the diagnosis of ADHD, it may identify an
802 alternative diagnosis and inform treatment and other interventions, including referral for trauma-
803 focused therapy and reporting suspected abuse.

804

805 *Mental Health Conditions*

806

807 In children or adolescents who have coexisting mild depression, anxiety, or obsessive-
808 compulsive disorder, the PCC may undertake the treatment of *all* disorders, if doing so is within
809 his or her abilities. Another option is to collaborate with a mental health clinician to treat the
810 coexisting condition, while the PCC oversees the ADHD treatment. As a third option, the
811 consulting specialists may advise about the treatment of the coexisting condition to the extent
812 that the PCC is comfortable treating both ADHD and the coexisting problems. With some
813 coexisting psychiatric disorders—such as severe anxiety, depression, autism, schizophrenia,
814 obsessive-compulsive disorder, oppositional defiant disorder, conduct disorder, and bipolar
815 disorder—a comanaging developmental-behavioral pediatrician or child and adolescent
816 psychiatrist might take responsibility for treatment of both ADHD and the coexisting illness.

817

818 Many children with ADHD exhibit emotion dysregulation, which is considered to be a
819 common feature of the disorder and one that is potentially related to other executive functioning
820 deficits.⁶⁹ A child exhibiting emotion dysregulation with either or both positive (eg, exuberance)
821 or negative (eg, anger) emotions along with symptoms of ADHD can be considered as a good
822 candidate for an ADHD diagnosis. Sometimes behavior related to emotion dysregulation can
823 lead the PCC to consider other diagnoses such as disruptive mood dysregulation disorder,
824 intermittent explosive disorder, and bipolar disorder. All 3 may be diagnosed with ADHD.
825 Intermittent explosive disorder and bipolar disorder are rare in children and data are currently
826 inadequate to know the prevalence of disruptive mood dysregulation disorder. Given the base
827 rates, these other diagnoses are unlikely, although they do occur in childhood. If the PCC has any
828 uncertainty about making these distinctions, referring the child to a clinical child psychologist or
829 child mental health professionals may be warranted.

830

831 *Learning Disabilities*

832

833 Learning disabilities frequently co-occur with ADHD and can lead to symptoms and
834 impairment that are similar to those in children with ADHD. As a result, screening for learning
835 disabilities' presence, such as via the Vanderbilt ADHD Rating Scale,⁷⁰ is important, given that
836 treatment for ADHD and learning disabilities differ markedly.

837

838 Learning disabilities involve impairment related to learning specific academic content—
839 usually reading or math, although there is increased awareness about disorders of written
840 expression. The impairment is not attributable to difficulties with sustaining attention; however,
841 some children with learning disabilities have trouble sustaining attention in class because they

842 cannot keep up and then disengage. A careful evaluation for learning disabilities includes
843 achievement testing, cognitive ability testing, and measures of the child's learning in response to
844 evidence-based instruction. Such thorough evaluations are typically not available in a PCC
845 practice. If screening suggests the possibility of learning disabilities, the PCC can help advise
846 parents on how to obtain school psychoeducational evaluations or refer to a psychologist or other
847 specialist trained in conducting these evaluations.

848

849 The PCC's attention is directed to language skills in preschool-aged and young school-
850 aged children, because difficulties in language skills can be a symptom of a language disorder
851 and predictor of subsequent reading problems. Language disorders may present as problems with
852 attention and impulsivity. Likewise, social interactions need to be noted during the examination,
853 because they may be impaired when the child or adolescent's language skills are delayed or
854 disordered.

855

856 Children who have intellectual or other developmental disabilities may have ADHD, but
857 assessment of these patients is more difficult, because a diagnosis of ADHD would only be
858 appropriate if the child or adolescent's level of inattention or hyperactivity/impulsivity is
859 disproportionate to his or her *developmental* rather than *chronological* age. Therefore,
860 assessment of ADHD in individuals with intellectual disabilities requires input from the child or
861 adolescent's education specialists, school psychologists, and/or independent psychologists.
862 Although it is important to attempt to differentiate whether the presenting problems are
863 associated with learning disabilities, ADHD, or something else, it is important to consider the
864 possibility that a child has multiple disorders. Pediatricians and other PCCs who are involved in
865 assessing ADHD in children with intellectual disabilities will need to collaborate closely with
866 school or independent psychologists.

867

868 *Summary*

869

870 Overall, there are many factors that influence a diagnostic decision. Frequently, these
871 decisions must be made without the benefit of all of the relevant information described. Family
872 and cultural issues that affect parents' expectations for their child and perceptions about mental
873 health can further complicate this process. Poverty, family history, access to care, and many
874 other factors that a PCC will probably not know when making the diagnosis can also be
875 formative in the child's presenting problems.⁵⁻⁹ The PCC will wisely remain sensitive to
876 individual variations in parents' beliefs, values and perception of their culture and community
877 when completing the assessment and determining a diagnosis. These factors add complexities to
878 the assessment and diagnostic process and make a good evaluation and diagnosis a function of
879 clinical experience, judgment, and a foundation in science.

880

881 **IV. TREATMENT**

882

883

884

885


886

887

888

889

890



IV a. Establish Management Team: Identify the Patient as a "Child With Special Health Care Needs"

Any child who meets the criteria for ADHD is considered a "child or youth with special health care needs"; these children are best managed in a medical home.⁷¹⁻⁷⁵ In addition, the AAP encourages clinicians to develop systems to allow the medical home to meet all needs of children with chronic illnesses. These needs—and strategies for meeting them—are discussed in further detail in AAP resources such as The Building Your Medical Home Toolkit and Addressing Concerns in Primary Care: A Clinician's Toolkit. Care in the medical home is reviewed in the AAP publication *Bright Futures: Guidelines for Health Supervision of Infants, Children, and Adolescents*, 4th Edition. Pediatricians and other PCCs who provide effective medical homes identify family strengths and recognize the importance of parents in the care team.⁷⁶⁻⁷⁹ The PCC may provide education about the disorder and treatment options, medication, and/or psychosocial treatment and monitor response to treatments over time as well as the child's development.

IV b. Establish Management Team: Collaborate With Family, School, and Child to Identify Target Goals

ADHD is a chronic illness; hence, education for both the child or adolescent and other family members is a critical element in the care plan. Family education involves *all* members of

918 the family, including the provision of developmentally age-appropriate information for the
919 affected child or adolescent and any siblings. Topics may include: the disorder's potential causes
920 and typical symptoms; the assessment process; common coexisting disorders; ADHD's effect on
921 school performance and social participation; long-term sequelae; and treatment options and their
922 potential benefits, adverse effects, and long-term outcomes. It is important to address the
923 patient's self-concept and clarify that having ADHD does not mean that the child is less smart
924 than others. At every stage, education must continue in a manner consistent with the
925 child/adolescent's level of understanding.

926

927 The emphasis for parental education is on helping parents understand the disorder, how to
928 obtain additional accurate information about ADHD and treatments, and how to effectively
929 advocate for their child. This may include addressing parental concerns about labeling the child
930 or adolescent with a disorder by providing information on the benefits of diagnosis and
931 treatment.

932

933 Some guidance about effective parenting strategies may be helpful, but Parent Training in
934 Behavior Management (PTBM) is likely to be most beneficial for most parents (see the section
935 on psychosocial treatments). Pediatricians and other PCCs are encouraged to be cognizant of the
936 challenges families may face in order to attend such training, including taking time off from
937 work and covering the costs associated with the intervention.

938

939 Parents may benefit from learning about optimal ways to partner with schools,
940 particularly their child's teachers, and become part of the educational and intervention teams.
941 Educating parents about special education and other services can be helpful, but school
942 interventions and advocacy may be best aided by partnering closely with an advocate or clinician
943 experienced in working with schools (see the psychosocial treatment section). With the parent's
944 permission, the clinician may provide educators at the school with information from the
945 evaluation that will help the school determine eligibility for special education services or
946 accommodations and/or develop appropriate services.

947

948 In addition, it is helpful to provide assistance to the parent or other caregiver in
949 understanding and using any relevant electronic health record (EHR) system. Sometimes, the
950 health literacy gap around electronic health records can lead to confusion and frustration on the
951 family's side. Also, providing information on community resources, such as other health care
952 providers or specialists, can be beneficial in addressing fragmentation and communication
953 barriers.

954

955 Family education continues throughout the course of treatment, and includes anticipatory
956 guidance in areas such as transitions (eg, from elementary to middle school, middle to high
957 school, and high school to college or employment); working with schools; and developmental
958 challenges that may be affected by ADHD, including driving, sexual activity, and substance use
959 and abuse. For parents who are interested in understanding the developmental aspects of
960 children's understanding about ADHD (ie, causes, manifestations, treatments), several AAP
961 publications may be useful.⁸⁰⁻⁸²

962

963 Although having a child diagnosed with ADHD can sometimes provide relief for
964 families, it is important to check on the parents' well-being. Having a disruptive child who has
965 trouble interacting with others can be very stressful for parents, and learning that their child has a

966 disorder sometimes gives them something to blame other than themselves. Helping families cope
967 with parenting challenges or making referrals for services to address their stress or depression
968 can be an important part of care. These concerns are particularly relevant when a parent has
969 ADHD or associated conditions. Parents may require support balancing the needs of their child
970 with ADHD and their other children's needs. Advocacy and support groups such as The National
971 Resource on ADHD (a program of Children and Adults with Attention-Deficit/Hyperactivity
972 Disorder [CHADD], <https://chadd.org/about/about-nrc/>) and the Attention Deficit Disorder
973 Association (www.add.org) can provide information and support for families. There also may be
974 local support organizations. The ADHD Toolkit provides lists of educational resources,
975 including Internet-based resources, organizations, and books that may be useful to parents and
976 children.

977

IV c. Establish Management Team: Establish Team and Coordination Plan

979

Treatment Team

981

982 The optimal treatment team includes everyone involved in the care of the child: the child,
983 parents, teachers, PCC, therapists, subspecialists, and other adults (such as coaches or faith
984 leaders) who will be actively engaged in supporting and monitoring the treatment of ADHD.⁷⁶⁻⁷⁹
985 It is helpful for the PCC or another assigned care coordinator to make each team member aware
986 of his or her role, the process and timing of routine and as-needed communication strategies, and
987 expectations for reports (ie, frequency, scope). Collaboration with school personnel goes beyond
988 the initial report of diagnosis and is best facilitated by agreement on a standardized, reliable
989 communication system. Although there are obstacles to achieving this level of coordination, if
990 successful, it enhances care and improves outcomes for the child. (See supplemental paper
991 "Systemic Barriers to the Care of Children and Adolescents With ADHD" for a discussion of
992 systemic challenges.)

993

Treatment Goals

995

996 Management plans include the establishment of treatment goals for the areas of concern, such
997 as those most commonly affected by ADHD: academic performance; relationships with peers,
998 parents, and siblings; and safety. It is not necessary to develop goals in every area at once.
999 Families might be encouraged to identify up to 3 of the most impairing areas to address initially.
1000 Parents and the child or adolescent can add other targets as indicated by their relative
1001 importance. Other goals may be identified using the International Classification of Function
1002 (ICF) analysis conducted in the diagnostic phase of the clinical pathway. This process increases
1003 the understanding of ADHD's effects on each family member and may lead to improved
1004 collaboration in developing a few specific and measurable outcomes. It is helpful to incorporate
1005 a child's strengths and resilience when considering target goals and generating the treatment
1006 plan. Academic or school goals require the input of teachers and other personnel for both
1007 identification and measurement.

1008

1009 Establishing measurable goals in interpersonal domains and improving behavior in
1010 unstructured settings may be particularly important. Wherever possible, progress should be
1011 quantifiable to monitor the frequency of behaviors. The number of achieved and missed goals
1012 per day can be recorded by the parent, child, and/or teacher. Charts may be suggested as
1013 strategies to record events so that parents, teachers, children, and PCCs can agree on how much

1014 progress has been made building success in a systematic and measurable way. Keeping the focus
1015 on progress toward the identified goals can keep all family members engaged, provide a rubric
1016 for measuring response to various treatments, and offer a vehicle for rewarding success. Such
1017 strategies can help a family accurately assess and see progress of behavior changes. A single
1018 page daily report card can be utilized to identify and monitor 4 or 5 behaviors that affect function
1019 at school and the card can be shared with parents. Other strategies and tools are available to
1020 clinicians in the AAP ADHD Provider Toolkit (3rd Edition),⁸³ and for parents, *ADHD: What*
1021 *Every Parent Needs to Know*.⁸⁴

1022
1023 As treatment proceeds, in addition to utilizing a *DSM-5*-based ADHD rating scale to
1024 monitor core symptom changes, formal and informal queries can be made in the areas affected
1025 by ADHD. At every visit, it is helpful for the PCC to gradually further empower
1026 children/adolescents so they are able to be full partners in the treatment plan by adolescence.
1027 Data from school are helpful at these visits—including rating scales completed by the child or
1028 adolescent’s teacher, grades, daily behavior ratings (when available), and formal test results.
1029

1030 *Management Plan*

1031
1032 In addition to educating the family, the PCC can consider developing a management plan
1033 that, over time, addresses the following questions:

- 1034 • Does the family need further assistance in understanding the core symptoms of ADHD and
1035 the child/adolescent’s target symptoms and coexisting conditions?
- 1036 • Does the family need support in learning how to establish, measure, and monitor target
1037 goals?
- 1038 • Have the family’s goals been identified and addressed in the care plan?
- 1039 • Does the family have an understanding of effective behavior management techniques for
1040 responding to tantrums, oppositional behavior, and/or poor compliance with requests or
1041 commands?
- 1042 • Does the family need help on normalizing peer and family relationships?
- 1043 • Does the child need help in academic areas? If so, has a formal evaluation been performed
1044 and reviewed to distinguish work production problems secondary to ADHD or attributable to
1045 coexisting learning or language disabilities?
- 1046 • Does the child or adolescent need assistance in achieving independence in self-help or
1047 schoolwork?
- 1048 • Does the child or adolescent or family require help with optimizing, organizing, planning, or
1049 managing schoolwork?
- 1050 • Does the family need help in recognizing, understanding, or managing coexisting conditions?
- 1051 • Does the family have a plan to educate the child or adolescent systematically about ADHD
1052 and its treatment, as well as the child’s own strengths and weaknesses?
- 1053 • Does the family have a plan to empower the child or adolescent with the knowledge and
1054 understanding that will increase their adherence to treatments? Has that plan been initiated
1055 and is it pitched at the child or adolescent’s developmental level?
- 1056 • Does the family have a copy of a care plan that summarizes the evaluation findings and
1057 treatment recommendations?
- 1058 • Does the follow-up plan provide comprehensive, coordinated, family-centered, and culturally
1059 competent ongoing care?

1060 • Does the family have any needed referrals to specialists to provide additional evaluations,
1061 treatments, and support?
1062 • Does the family have a plan for the transition from pediatric to adult care that provides the
1063 transitioning youth with the necessary ADHD self-management skills, understanding of
1064 health care and educational privacy laws, identified adult clinician to continue his or her
1065 ADHD care, and health insurance coverage?

1066

1067 **IV d. Treatment: Medication, Psychosocial Treatment, and Collaboration With the School to**
1068 **Enhance Support Services**

1069

1070 The decision about the most acceptable treatment for the child rests with the family and
1071 its decisions about treatment. The PCC needs to encourage that this decision is based on accurate
1072 and adequate information, which often involves correcting misinformation or unwarranted
1073 concerns about medication. If the family still declines medication treatment, the PCC can
1074 encourage all other types of effective treatment and provide appropriate monitoring (families
1075 who decline medication are discussed in more detail below).

1076

1077 Pediatricians and other PCCs need to educate families about the benefits and
1078 characteristics of evidence-based ADHD psychosocial treatment and explicitly communicate that
1079 play therapy and sensory-related therapies have *not* been demonstrated to be effective. Likewise,
1080 for children younger than 7 years, individual CBT lacks demonstrated effectiveness; CBT has
1081 some, but not strong, evidence for children 7 to 17 years of age. Families should be made aware
1082 that for psychosocial treatments to be effective, the therapist needs to work with the family (not
1083 just the child or adolescent) on setting and maintaining routines, discipline and reward-related
1084 procedures, training programs, and creating a home environment that will bring out the best in
1085 the child and minimize ADHD-related dysfunction.

1086

1087 (See ADHD Guideline Key Action Statements #5 and #6.)

1088

1089 *Treatment: Medication*

1090

1091 This treatment option is restricted to children and adolescents who meet diagnostic
1092 criteria for ADHD.

1093

1094 The US Food and Drug Administration (FDA) has approved stimulant medications (ie,
1095 methylphenidate and amphetamines) and several nonstimulant medications for the treatment of
1096 ADHD in children and adolescents. New brands of methylphenidate and amphetamines continue
1097 to be introduced, including longer-acting products, various isomeric products, and delayed-
1098 release products. Hence, it is increasingly unlikely that pediatricians and other PCCs need to
1099 consider the off-label use of other medications. A free and continually updated list of
1100 medications is available at www.ADHDMedicationGuide.com. (See the ADHD guideline for
1101 information on off-label use.)

1102

1103 With the expanded choices and considerations of the clinical effects comes the reality
1104 that clinical choices are often heavily restricted by insurance coverage. Some, but not all, of the
1105 problems include changes in insurance and formulary that preclude the use of certain
1106 medications or force a stable patient to change medications, step therapy requirements that may
1107 delay effective treatment, and financial barriers that preclude a patient's use of newer drugs or

1108 those not preferred by the payer. (See the supplemental paper “Systemic Barriers to the Care of
1109 Children and Adolescents with ADHD” for a discussion of this issue.)
1110

1111 The choice of stimulant medication formulation depends on such factors as the efficacy
1112 of each agent for a given child, the preferred length of coverage, whether or not a child can
1113 swallow pills or capsules, and out-of-pocket costs. The extended-release formulations are
1114 generally more expensive than the immediate-release formulations. Families and children may
1115 prefer them, however, because of the benefits of consistent and sustained coverage with fewer
1116 daily administrations. Long-acting formulations usually avoid the need for school-based
1117 administration of ADHD medication. Better coverage with fewer daily administrations leads to
1118 greater convenience to the family and is linked with increased adherence to the medication
1119 management plan.⁸⁵
1120

1121 Some patients, particularly adolescents, may require more than 12 hours of coverage
1122 daily to ensure adequate focus and concentration during the evening, when they are more likely
1123 to be studying and/or driving. In these cases, a nonstimulant medication or short-acting
1124 preparation of stimulant medication may be used in the evening in addition to a long-acting
1125 preparation in the morning. Of note, stimulant medication treatment of individuals with ADHD
1126 has been linked to better driving performance and a significant reduced risk of motor vehicle
1127 crashes.⁸⁶
1128

1129 The ease with which preparations can be administered and the minimization of adverse
1130 effects are key quality-of-life factors and are important concerns for children, adolescents, and
1131 their parents. When making medication recommendations, PCCs has to consider the time of day
1132 when the targeted symptoms occur, when homework is usually done, whether medication
1133 remains active when teenagers are driving, whether medication alters sleep initiation, and risk
1134 status for substance use or stimulant misuse or diversion.
1135

1136 All FDA-approved stimulant medications are methylphenidate or amphetamine
1137 compounds and have similar desired and adverse effects. Given the extensive evidence of
1138 efficacy and safety, these drugs remain the first choice in medication treatment. The decision
1139 about what compound a PCC prescribes first should be made on the basis of individual clinician
1140 and family preferences and the child’s age. Some children will respond better to, or experience
1141 more adverse effects with, 1 of the 2 stimulants groups (ie, methylphenidate or amphetamine)
1142 over another. Because this cannot be determined in advance, medication trials are appropriate. If
1143 a trial with 1 group is unsuccessful because of poor efficacy or significant adverse effects, a
1144 medication trial with medication from the other group should be undertaken. At least half of
1145 children who fail to respond to 1 stimulant medication have a positive response to the alternative
1146 medication.⁸⁹
1147

1148 Of note, recent meta-analyses have documented some subtle group-level differences in
1149 amphetamine/dextroamphetamine and methylphenidate response. One such analysis found that,
1150 on average, youth with ADHD who were treated with either amphetamine- or methylphenidate-
1151 based medications showed improvement in ADHD symptoms.⁸⁷ There was a marginally larger
1152 improvement in clinicians’ ADHD symptom ratings for amphetamine-based versus
1153 methylphenidate-based preparations.⁸⁷ This meta-analysis indicated that overall adverse effects
1154 (including sleep problems and emotional side effects) were more prominent among those using
1155 amphetamine-based preparations. The findings were corroborated by a 2018 meta-analysis,

1156 which found that amphetamine/dextroamphetamine worsened emotional lability compared with
1157 the premedication baseline. The meta-analysis found there was a tendency for methylphenidate
1158 to reduce irritability and anxiety, compared with the patients' premedication ratings.⁸⁸ Among
1159 individual patients, medication's efficacy and adverse effects can vary from these averages.
1160

1161 Families who are concerned about the use of stimulants or the potential for their abuse
1162 and/or diversion may choose to start with atomoxetine, extended-release guanfacine or extended-
1163 release clonidine. In addition, those not responding to either stimulant group may still respond to
1164 atomoxetine, extended-release guanfacine, or
1165 extended-release clonidine.
1166

1167 Atomoxetine is a selective
1168 norepinephrine reuptake inhibitor that may
1169 demonstrate maximum response after
1170 approximately 4 to 6 weeks of use, although
1171 some patients experience modest benefits after
1172 1 week of atomoxetine treatment. Extended-
1173 release guanfacine and extended-release
1174 clonidine are alpha-2A adrenergic agonists that
1175 may demonstrate maximum response in about 2
1176 to 4 weeks. It is worth making families aware
1177 that symptom change is more gradual with
1178 atomoxetine and alpha-2A adrenergic agonists
1179 than the rapid effect seen with stimulant
1180 medications. Atomoxetine may cause
1181 gastrointestinal tract symptoms and sedation
1182 early on, so it is recommended to prescribe half
1183 the treatment dose (0.5 mg/kg) for the first
1184 week. Appetite suppression can also occur.
1185 Both alpha-2A agonists can cause the adverse
1186 effect of somnolence. It is recommended that
1187 alpha-2A agonists be tapered when discontinued to prevent possible rebound hypertension.
1188

1189 In patients who only respond partially to stimulant medications, it is possible to combine
1190 stimulant and nonstimulant alpha-2 agonist medications to obtain better efficacy (see the clinical
1191 practice guideline). It is helpful to ask the family if they have any prior experience with any of
1192 the medications, because a prior good or bad experience in other family members may indicate a
1193 willingness or reluctance to use one type or a specific stimulant medication. When there is
1194 concern about possible use or diversion of the medication, or a strong family preference against
1195 stimulant medication, an FDA-approved nonstimulant medication may be considered as the first
1196 choice of medication.
1197

1198 Medications that utilize a microbead technology can be opened and sprinkled on food and
1199 are, therefore, suitable for children who have difficulty swallowing tablets or capsules. For
1200 patients who are unable to swallow pills, alternative options include immediate- and extended-
1201 release methylphenidate and amphetamine in a liquid and chewable form, a methylphenidate
1202 transdermal patch, and an orally disintegrating tablet.
1203

**There is a Black Box warning on
atomoxetine about the possibility of
suicidal ideation when initiating
medication management. Early symptoms
of suicidal ideation may include thinking
about self-harm and increasing agitation. If
there are any concerns about suicidal
ideation in children prescribed
atomoxetine, further evaluation (ie, using
the Patient Health Questionnaire-9 rating
scale, asking about suicidal ideation,
reviewing presence of firearms in the
home, determining whether there is good
communication between the patient and
parents or trusted adults, etc),
reconsideration about the use of
atomoxetine, and more frequent
monitoring should be considered; referral
to a mental health clinician may be
necessary.**

1204 It is often helpful to inform families that the initial medication titration process may take
1205 several weeks to complete and medication changes can be made on a weekly basis, and
1206 subsequent changes in medication may be necessary. Completion of ADHD rating scales prior to
1207 dose adjustment helps promote measurement-based treatment. The usual procedure is to begin
1208 with a low dose of medication and titrate to the dose that provides maximum benefit and minimal
1209 adverse effects. Core symptom reduction can be seen immediately with stimulant medication
1210 initiation, but improvements in function require more time to manifest. Stimulant medications
1211 can be effectively titrated with changes occurring in a 3- to 7-day period. During the first month
1212 of treatment, the medication dose may be titrated with a weekly or biweekly follow-up. The
1213 increasing doses can be provided either by prescriptions that allow dose adjustments upward or,
1214 for some of medications, by one prescription of tablets/capsules of the same strength with
1215 instructions to administer progressively higher amounts by doubling or tripling the initial dose.
1216

1217 Another approach, similar to the one used in the Multimodal Treatment of ADHD (MTA)
1218 study,⁸⁹ is for parents to be directed to administer different doses of the same preparation, each
1219 for 1 week at a time (eg, Saturday through Friday). At the end of each week, feedback from
1220 parents and teachers, and/or *DSM-5*-based ADHD rating scales, can be obtained through a phone
1221 interview, fax, or a secure electronic system. In addition to the ADHD rating scale, parents and
1222 teachers can be asked to review adverse effects and progress on target goals.
1223

1224 Follow-up Visits

1225 A face-to face follow-up visit is recommended at about the fourth week after starting the
1226 medication. At this visit, the PCC reviews the child or adolescent's responses to the varying
1227 doses and monitors adverse effects, pulse, blood pressure, and weight. To promote progress in
1228 controlling symptoms is maintained, PCCs will continue to monitor levels of core symptoms and
1229 improvement in specified target goals. ADHD rating scales should be completed at each visit,
1230 particularly before any changes in medication and/or dose.
1231

1232 In the first year of treatment, face-to-face visits to the PCC are recommended to occur on
1233 a monthly basis until consistent and optimal response has been achieved, then every 3 months.
1234 Subsequent face-to-face visits will be dependent on the response; they typically occur quarterly
1235 but need to occur at least twice annually until it is clear that target goals are progressing and
1236 symptoms have stabilized. Thereafter, visits occur periodically as determined by the family and
1237 the PCC. After several years, if the child or adolescent is doing well and wants to attempt a trial
1238 off of the medication, this can be initiated.
1239

1240 Results from the MTA study suggest that there are some children who, after 3 years of
1241 medication treatment, continue to improve even if the medication is discontinued.⁹⁰ These
1242 findings suggest that children who are stable in their improvement of ADHD symptoms may be
1243 given a trial off medication after extended periods of use to determine whether medication is still
1244 needed. This process is best undertaken with close monitoring of the child's core symptoms and
1245 function at home, in school, and in the community. If pharmacologic interventions do not
1246 improve the child or adolescent's symptoms, the diagnosis needs to be reassessed (see treatment
1247 failure section).
1248

1249 Whenever possible, improvements in core symptoms and target goals should be
1250 monitored in an objective way (eg, an increase from 40% goal attainment to 80% per week; see
1251

1252 the ADHD Toolkit for more information). Core symptoms can be monitored with one of the
1253 *DSM-5*-based ADHD rating scales.

1254
1255 Pediatricians and other PCCs are encouraged to educate parents that, although
1256 medications can be effective in facilitating schoolwork, they have not been shown to be effective
1257 in addressing learning disabilities or a child's level of motivation. A child or adolescent who
1258 continues to experience academic underachievement after attaining some control of his or her
1259 ADHD behavioral symptoms needs to be assessed for a coexisting condition. Such coexisting
1260 conditions include learning and language disabilities, other mental health disorders, and other
1261 psychosocial stressors. This assessment is part of the initial assessment in children who present
1262 with difficulties in keeping up with their schoolwork and grades and who are rated as having
1263 problems in the 3 academic areas (ie, reading, writing, and math).

1264
1265 *Treatment: Psychosocial Treatment*

1266
1267 Two types of psychosocial treatments are well-established for children and adolescents
1268 with ADHD, including some behavioral treatments and training.⁹¹

1269
1270 Behavioral Treatments

1271
1272 There is a great deal of evidence supporting the use of behavioral treatments for
1273 preschool and elementary and middle school-aged children, including several types of PTBM
1274 and classroom interventions (see the clinical practice guideline for more information). There are
1275 multiple PTBM programs available, which are reviewed in the ADHD Toolkit.⁸³

1276
1277 Evidence-based PTBM training typically begins with 7 to 12 weekly group or individual
1278 sessions with a trained or certified therapist. Although PTBM treatments differ, the primary
1279 focus is on helping parents improve the methods they use to reward and motivate their child in
1280 order to reduce the behavioral difficulties posed by ADHD and improve their children's
1281 behavior. Therapists help parents establish consistent relationships or contingencies between the
1282 child's specific behaviors and the parents' use of rewards or logical consequences for
1283 misbehavior. These treatments typically use specific directed praise, point systems, time outs,
1284 and privileges to shape behavior. Parents learn how to effectively communicate expectations and
1285 responses to desirable and undesirable behaviors.

1286
1287 PTBM programs offer specific techniques for reinforcing adaptive and positive behaviors
1288 and decreasing or eliminating inappropriate behaviors, which alter the motivation of the
1289 child/adolescent to control attention, activity, and impulsivity. These programs emphasize
1290 establishing positive interactions between parents and children, shaping children's behaviors
1291 through praising and strengths-spotting, giving successful commands, and reinforcing positive
1292 behaviors. They help parents to extinguish inappropriate behaviors through ignoring, to identify
1293 behaviors that are most appropriately handled through natural consequences, and to use natural
1294 consequences in a responsible way.

1295
1296 These programs all emphasize teaching self-control and building positive family
1297 relationships. If parents strongly disagree about behavior management or have contentious
1298 relationships, parenting programs will likely be unsuccessful. Depending on the severity of the
1299 child/adolescent's behaviors and the capabilities of the parents, group or individual training

1300 programs will be required. Programs may also include support for maintenance and relapse
1301 prevention.

1302
1303 Although all effective parenting uses behavioral techniques, applying these strategies to
1304 children or adolescents with ADHD requires additional rigor, adherence, and persistence,
1305 compared with children without the disorder. Some PTBM programs include additional
1306 components such as education about ADHD, development and other related issues, motivational
1307 interviewing, and support for parents coping with a child with ADHD.

1308
1309 PTBM training has been modified for use with adolescents to incorporate a family
1310 therapy approach that includes communication, problem-solving, and negotiation. Initially
1311 developed for adolescents with a wide range of problems,⁹⁴ this approach has been modified for
1312 adolescents with ADHD.^{93,94} The approach's effects are not as large as with PTBM training with
1313 children, but clear benefits have been reported; this is a feasible clinic-based approach that
1314 warrants a referral, if available.

1315
1316 Although PTBM training is typically very effective, such programs may not be available
1317 in many areas (see supplemental paper "Systemic Barriers to the Care of Children and
1318 Adolescents with ADHD" for further discussion of this issue¹). Factors that may diminish
1319 PTBM's effects and/or render them ineffective include the time commitment required to attend
1320 sessions and practice the recommendations at home, particularly given other competing demands
1321 for the family's time. Parental disagreements about implementing the PTBM program, conflicts
1322 between parents, and separated parents who share caretaking responsibilities can adversely affect
1323 the results. Careful monitoring of progress and follow-up by the therapist or PCC can reduce the
1324 likelihood of these risks. PTBM training may not be covered by health insurance (insurance
1325 issues are discussed in the supplemental barriers paper).

1326
1327 **Training Interventions**

1328
1329 Training interventions are likely to be effective with children and adolescents with
1330 ADHD. These interventions involve targeting specific deficiencies in skills such as study,
1331 organization, and interpersonal skills. Effective training approaches involve targeting a set of
1332 behaviors that are useful to the child in daily life, and providing extensive training, practice, and
1333 coaching over an extended period of time. For some children, the combination of behavioral
1334 treatments and training may be most effective. Psychosocial treatments are applicable for
1335 children who have problems with inattentive or hyperactive/impulsive behaviors but do not meet
1336 the *DSM-5* criteria for a diagnosis of ADHD.

1337
1338 Many of the behavioral and training treatments described above can be provided at
1339 school. Coaching, which has emerged as a treatment modality over the last decade, can be a
1340 useful alternative to clinic- or school-based treatments. There has yet to be rigorous studies to
1341 support its benefits, although it has good face validity. Currently, there is no standardized
1342 training or certification for coaches.

1343
1344 **Other Considerations**

1345
1346 PCCs can make recommendations about treatments that are most likely to help a child or
1347 adolescent with ADHD and discourage the use of nonmedication treatments that are unlikely to

1348 be effective. Pediatricians and other PCCs are encouraged to discuss what parents have tried in
1349 the past, and what has been beneficial for the child and his or her family.

1350
1351 Treatments for which there is insufficient evidence include large doses of vitamins and
1352 other dietary alterations; vision/visual training; chelation; electroencephalographic (EEG)
1353 biofeedback; and working memory (ie, cognitive training) programs.⁹¹ To date, there is
1354 insufficient evidence to determine that these therapies lead to changes in ADHD's core
1355 symptoms or functioning. There is a lack of information about the safety of many of these
1356 alternative therapies. Although there is some minimal information that significant doses of
1357 essential fatty acids may help with ADHD symptoms, further study on effectiveness, negative
1358 impacts, and adverse effects is needed before it can be considered a recommended treatment.⁹⁵

1359
1360 As noted, some therapies that are effective for other disorders are *not* supported for use
1361 with children or adolescents with ADHD. These include CBT (which has documented
1362 effectiveness for the treatment of anxiety and depressive disorders), play therapy, social skills
1363 training, and interpersonal talk therapy. Although it is possible that these treatments may
1364 improve ADHD symptoms in a *specific* child or adolescent, they are less likely to do so
1365 compared with evidence-based treatments. As a result, the PCC should discourage use of these
1366 approaches. If these ineffective treatments are attempted before evidence-based modalities,
1367 parents may erroneously conclude that *all* mental health treatments are ineffective. For example,
1368 if CBT or play therapy does not help their child's ADHD, parents may dismiss other treatments,
1369 like PTBM, which could be helpful. Parents also may discount CBT if it subsequently is
1370 recommended for an emerging anxiety disorder.

1371
1372 Pediatricians and other PCCs are unlikely to be effective in providing psychosocial
1373 treatment unless they are specifically trained, have trained staff, are co-located with a therapist,
1374 or dedicate multiple visits to providing this treatment. Clinicians may have difficulty determining
1375 whether the therapists listed in the patient's health insurance plan have the requisite skills to
1376 provide evidence-based, psychosocial ADHD-related treatment. This determination is important,
1377 because many therapists focus on a play therapy or interpersonal talk therapy, which have *not*
1378 been shown to be effective in treating the impairments associated with ADHD.

1379
1380 Pediatricians and other PCCs may want to develop a resource list of local therapists,
1381 agencies, and other mental health clinicians who can treat these impairments. Clinicians might
1382 request references from other parents of children with ADHD, professional organizations (eg, the
1383 Association for Behavior and Cognitive Therapies), and ADHD advocacy organizations (eg,
1384 CHADD). Parents who have read authoritatively written books about psychosocial treatment
1385 may be in a better position to know what they are looking for in a therapist. Some of these
1386 resources are available in the ADHD Toolkit⁸³ and in *ADHD: What Every Parent Needs to*
1387 *Know*⁸⁴ as well as other online sources.^{84,96-98} Unfortunately, lack of insurance coverage,
1388 availability, and accessibility of effective services may limit the implementation of this process
1389 (see supplemental paper "Systemic Barriers to the Care of Children and Adolescents with
1390 ADHD" for further discussion).

1391
1392 *Treatment: Collaborate With School to Enhance Support and Services*
1393

1394 School-based approaches have demonstrated both short- and long-term benefits for at
1395 least 1 year beyond treatment.^{99,100} Schools can implement behavioral or training interventions

1396 that directly target ADHD symptoms and interventions to enhance academic and social
1397 functioning. Schools may use strategies to enhance communication with families, such as daily
1398 behavior report cards. All schools should have specialists (eg, school psychologists, counselors,
1399 special educators) who can observe the child or adolescent, identify triggers and reinforcers, and
1400 support teachers in improving the classroom environment. School specialists can recommend
1401 accommodations to address ADHD symptoms, such as, untimed testing, testing in less
1402 distracting environments, and routine reminders. As children and adolescents get older, their
1403 executive functioning skills continue developing. So, their delays may decrease and they may no
1404 longer need the accommodations. Alternatively, further intervention may be indicated to
1405 facilitate the development of these independent skills.

1406
1407 It is helpful for PCCs to be aware of the eligibility criteria for 504 Rehabilitation Act and
1408 the Individuals with Disabilities Education Act (IDEA) support in their state and local school
1409 districts.¹⁰¹ It is helpful to understand the process for referral and the specific individuals to
1410 contact about these issues. Providing this information to parents will support their efforts to
1411 secure classroom adaptations for their child or adolescent, including the use of empirically
1412 supported academic interventions to address the achievement difficulties that are often associated
1413 with ADHD symptoms.

1414
1415 Educate Parents About School Services

1416
1417 School is often the place where many of a child or adolescent with ADHD's problems
1418 occur. Although services are available—through special education, IDEA, and Section 504
1419 plans—classroom teachers can help students with ADHD. Students with ADHD are most likely
1420 to succeed in effectively managed classrooms in which teachers provide engaging instruction,
1421 support their students, and implement rules consistently. School staff can sometimes consult with
1422 classroom teachers to help them improve their skills in these areas. In many schools, parents can
1423 ask the principal for a specific teacher for their child the following academic year.

1424
1425 In some schools, teachers may implement activities to help a student before he or she is
1426 considered for special services, including a daily report card, organization interventions,
1427 behavioral point systems, and coordinating with the parents—such as by using websites or portal
1428 systems for communication. Individualized behavioral interventions, if implemented well and
1429 consistently, are some of the most effective interventions for children with ADHD. In addition to
1430 individualized interventions, encouraging parents to increase communication with the teacher
1431 can help parents reinforce desirable behavior at school.

1432
1433 If these approaches are not adequate—or teachers are unwilling to provide them—parents
1434 can be encouraged to write to the principal or the director of special education requesting an
1435 evaluation for special education services. An evaluation from a PCC can help this evaluation
1436 process but is unlikely to replace it. A child who has an ADHD diagnosis may be eligible for
1437 special education services in the category of “other health impaired.” Depending on the specific
1438 nature of a child’s impairment at school, he or she may be eligible for the categories of
1439 “emotional and behavioral disorders” or “specific learning disability.” The category of eligibility
1440 does not affect the services available to the child but usually reflect the nature of the problems
1441 that resulted in his or her eligibility for special education services.

1442
1443 Although a PCC may recommend that a child is eligible for special education and

specific services, these are only recommendations, as specific evaluation procedures and criteria for eligibility are determined by each school district within federal guidelines. If the ADHD is severe and interfering with school performance, services are usually provided under the “other health impaired” category. It is important for PCCs to avoid using language in the report that could alienate people in the school or create conflict between the parents and school staff. After school staff complete the evaluation, a meeting will be held to review the results of all evaluation information (including the PCC report) and determine the student’s eligibility for an Individualized Education Program (IEP) or a 504 plan. The parents may invite others to attend the meeting, if they wish. Some communities have individuals who are trained to help parents effectively advocate for services; being aware of existing resources can help the PCC refer parents to them, if they exist. Additional details about eligibility are usually available on the school district’s and the state department of education’s websites.

A PCC can help educate the parents about the types of services they can request at the meeting. There are generally 2 categories of services. Some of the most common services are often referred to as “accommodations,” including extending time on tests; reducing homework; or providing a child with class notes from the teacher or a peer. These services reduce the expectations for a child and can quickly eliminate school problems. For example, if a child is failing classes because he or she is not completing homework and the teacher stops assigning the child homework, then the child’s grade in the class is likely to improve quickly. Similarly, parent-child conflict regarding homework will quickly cease. Although these outcomes are desirable, if discontinuing the expectation for completing homework results does not help improve the student’s ability to independently complete tasks outside school—which is an important life skill—it may not be beneficial. Although appealing, these services may not improve and in some cases may decrease the child’s long-term competencies. They need to be considered with this in mind.

The second set of services consists of interventions that enhance the student’s competencies. These take much more work to implement than the services described above and do not solve the problem nearly as quickly. Although appealing, these services may decrease the child’s long-term competencies if they are not combined with interventions that are aimed at improving the student’s skills and behaviors. Accommodations need to be considered with this broader context in mind. The advantage of interventions is that, over time, many students improve their competencies and become able to independently meet age-appropriate expectations (for more information on this approach, see the Life Course Model¹⁰²).¹⁰³ Interventions include organization interventions, daily report cards, and training study skills. The following school-based interventions have been found to be effective in improving academic and interpersonal skills for students with ADHD: Challenging Horizons Program,⁹⁹ Child Life and Attention Skills,¹⁰⁴ and Homework and Organization Planning Skills.¹⁰⁵ If these are available in area schools, it is important to encourage their use.

V. AGE-RELATED ISSUES

V.a. Preschool-Aged Children (Age 4 Years to the 6th Birthday)

Clinicians can initiate treatment of preschool-aged children with ADHD (ie, children age 4 years to the 6th birthday) with PTBM training and assess for other developmental problems, especially with language. If children continue to have moderate to severe dysfunction, the PCC needs to

1492 reevaluate the extent to which the parents can implement the therapy; the PCC can also consider
1493 prescribing methylphenidate, as described previously. Titration should start with a small dose of
1494 immediate-release methylphenidate, because preschool-aged children metabolize medication at a
1495 slower rate. They have shown lower optimal mg/kg daily doses than older children and may be
1496 more sensitive to emotional side effects such as irritability and crying.^{106,107}

1497
1498 Currently, dextroamphetamine is the only FDA-approved ADHD medication to treat
1499 preschool-aged children. However, when dextroamphetamine received FDA approval, the
1500 criteria were less stringent than they are now, so there is only sparse evidence to support its
1501 safety and efficacy in this age group. There is more abundant evidence that methylphenidate is
1502 safe and efficacious for preschool-aged children with ADHD. For this reason, methylphenidate is
1503 the first-line recommended ADHD medication treatment for this age group, despite not having
1504 FDA approval.¹⁰⁸

1505
1506 The Preschool Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS),¹⁰⁷ the
1507 landmark trial documenting methylphenidate's safety and efficacy in this age group, included
1508 children with moderate to severe dysfunction. Therefore, the recommendation for
1509 methylphenidate treatment is reserved for children with significant, rather than mild, ADHD-
1510 related impairment. In the Preschool Attention-Deficit/Hyperactivity Disorder Treatment Study
1511 trial, moderate to severe impairment was defined as having symptoms present for at least 9
1512 months and clear impairment in both the home and child care/preschool settings that did not
1513 respond to an appropriate intervention.

1514
1515 There is limited published evidence of the safety and efficacy for the preschool-aged
1516 group of atomoxetine, extended-release guanficine, or extended-release clonidine. None of these
1517 nonstimulant medications have FDA approval for this age group.¹⁰⁹

1518
1519 **Vb. Adolescents (Age 12 Years to the 18th Birthday)**

1520
1521 Pediatricians and other PCCs may increase medication adherence and engagement in the
1522 treatment process by closely involving adolescents (age 12 years to the 18th birthday) in
1523 medication treatment decisions. Collaborating with the adolescent to determine whether the
1524 medication is beneficial can help align outcome measures with the adolescent's own goals.
1525 Special attention ought to be paid to provide medication coverage at times when the adolescent
1526 may exhibit risky behaviors, such as when he or she is driving or spending unsupervised time
1527 with friends. Longer-acting or late-afternoon administration of nonstimulant medications or
1528 short-acting medications may be helpful.

1529
1530 If pediatricians and other PCCs begin transitioning children to be increasingly
1531 responsible for treatment decisions during early adolescence, then transitioning to a primary care
1532 physician who specializes in care for adults will be a natural continuation of that process when
1533 the adolescent reaches the highest grades in high school. Preparation for the transition to
1534 adulthood is an important step that includes planning for transferring care, adapting treatment to
1535 new activities and schedules, and educating the patient about effective ways to obtain insurance
1536 and engage in services.

1537
1538 Counseling for adolescents around medication issues needs to include dealing with
1539 resistance to treatment and empowering the patient to take charge of and own his or her


1540 medication management as much as possible. Techniques of motivational interviewing may be
1541 useful in improving adherence.¹¹⁰

1542
1543 In addition to the numerous developmental changes encountered when working with
1544 adolescents, PCCs should assess adolescent patients with ADHD for symptoms of substance use
1545 or abuse before beginning medication treatment. If substance use is revealed, the patient should
1546 stop the use. Referral for treatment for substance use must be provided before beginning
1547 treatment for ADHD (see the clinical practice guideline). Pediatricians and other PCCs should
1548 pay careful attention to potential substance use and misuse and diversion of medications.
1549 Screening for signs of substance use is important in the care of all adolescents and, depending on
1550 the amount of use, may lead a PCC to recommend treatment for substance use. Extensive use or
1551 abuse may result in concerns about continuing medication treatment for ADHD until the abuse is
1552 resolved. Similar concerns and consideration of discontinuing medication treatment for ADHD
1553 could emerge if there is evidence that the adolescent is misusing or diverting medications for
1554 other than its intended medical purposes. Pediatricians and other PCCs are encouraged to
1555 monitor symptoms and prescription refills for signs of misuse or diversion of ADHD medication.
1556 Diversion of ADHD medication is a special concern among adolescents.¹¹¹

1557
1558 When misuse or diversion is a concern, the PCC might consider prescribing nonstimulant
1559 medications with much less abuse potential, such as atomoxetine, extended-release guanfacine,
1560 or extended-release clonidine. It is more difficult but not impossible to extract the
1561 methylphenidate or amphetamine for abuse from the stimulant medications lisdexamfetamine,
1562 dermal methylphenidate, and OROS methylphenidate, although these preparations still have
1563 some potential for abuse or misuse.

1564
1565 PCCs should be aware that short-acting, mixed amphetamine salts are the most
1566 commonly misused or diverted ADHD medication. It is important to note that diversion and
1567 misuse of ADHD medications may be committed by individuals who have close contact with, or
1568 live in the same house as, the adolescent—not necessarily by the adolescent him or herself; this
1569 is especially true for college-aged adolescents. Pediatricians and other PCCs are encouraged to
1570 discuss safe storage practices, such as lockboxes for controlled substances, when used by
1571 college-aged adolescents.

1572
1573 **VI. MONITORING**
1574



1575
1576

1577 Pediatricians and other PCCs should regularly monitor *all* aspects of ADHD treatment
1578 including:
1579 • Systematic reassessment of *core symptoms and function*;
1580 • Regular reassessment of *target goals*;
1581 • *Family satisfaction with the care* it is receiving from other clinicians and therapists, if
1582 applicable;
1583 • Provision of *anticipatory guidance*, further *child/adolescent and family education*, and
1584 *transition planning* as needed and appropriate;
1585 • Occurrence and quality of *care coordination* to meet the needs of the child or adolescent and
1586 family;
1587 • Confirmation of *adherence* to any prescribed medication regimen, with adjustments made as
1588 needed;
1589 • *Heart rate, blood pressure, height, and weight monitoring*; and
1590 • *Furthering the therapeutic relationship* with the child or adolescent and empowering families
1591 and children or adolescents to be strong, informed advocates.

1592
1593 Some treatment monitoring can occur during general health care visits if the PCC
1594 enquires about the child or adolescent's progress toward target goals, adherence to medication
1595 and behavior therapy, concerns, and changes. This extra time and evaluation effort may generate
1596 an E/M along with the well-child care code and may result in an additional cost to the family (see
1597 the supplemental paper on barriers, specifically the compensation section¹). Monitoring of a
1598 child or adolescent with inattention or hyperactivity/impulsivity problems can help to ensure
1599 prompt treatment should symptoms worsen to the extent that a diagnosis of ADHD is warranted.

1600
1601 As treatment proceeds, in addition to using a *DSM-5*-based ADHD rating scale to
1602 monitor core symptom changes, the PCC can make formal and informal queries in the areas of
1603 function most commonly affected by ADHD: academic achievement; peer, parent, or sibling
1604 relationships; and risk-taking behavior. Progress can be measured by monitoring the target goals
1605 established in collaboration with the child and family. Checklists completed by the school can
1606 facilitate medication monitoring. Data from the school—including ADHD symptom ratings
1607 completed by the teacher as well as grades and any other formal testing—are helpful at these
1608 visits. Screening for substance use and sleep problems is best continued throughout treatment,
1609 because these problems can emerge at any time. At every visit, it is helpful to gradually further
1610 empower children to become full partners in their treatment plan by adolescence.

1611
1612 In the early stages of treatment, following a successful titration period, the frequency of
1613 follow-up visits will depend on adherence, coexisting conditions, family willingness, and
1614 persistence of symptoms. As noted, a general guide for visits to the primary care clinician is for
1615 these visits to occur initially on a monthly basis, then at least quarterly for the first year of
1616 treatment. More frequent visits may be necessary if comorbid conditions are present. Visits then
1617 need be held preferably quarterly but at least twice each year, with additional phone contact
1618 monitoring at the time of medication refill requests. Ongoing communication with the school
1619 regarding medication and services is needed.

1620
1621 There is little evidence establishing the optimal, practical follow-up regimen. It is likely
1622 that the regimen will need to be tailored to the individual child/adolescent and family needs
1623 based on clinical judgment. Follow-up may incorporate electronic collection of rating scales,

1624 telehealth, or use of remote monitoring of symptoms and impairment. The time-intensive nature
1625 of this process, insurance restrictions, and lack of payment may be significant barriers to
1626 adoption (see supplemental paper “Systemic Barriers to the Care of Children and Adolescents
1627 with ADHD” for more information on this issue).

1628
1629 (See ADHD Guideline’s Key Action Statement #4.)
1630

1631 **VI a. Treatment Failure**
1632

1633 ADHD treatment failure may be a sign of inadequate dosing, lack of patient or family
1634 information or compliance, or/and incorrect or incomplete diagnosis. Family conflict and
1635 parental psychopathology can also contribute to treatment failure.

1637 In the event of treatment failure, the PCC is advised to repeat the full diagnostic
1638 evaluation with increased attention to the possibility of another or comorbid conditions that
1639 mimic or are associated with ADHD, such as sleep disorders, autism spectrum disorders, or
1640 epilepsy (eg, absence epilepsy or partial seizures). Treatment failure may also arise from a new
1641 acute stressor or from an unrecognized or underappreciated traumatic event. A coexisting
1642 learning disability may cause an apparent treatment failure. In the case of a child or adolescent
1643 previously diagnosed with problem-level inattention or hyperactivity, repeating the diagnostic
1644 evaluation may result in a diagnosis of ADHD, which would allow for increased school support
1645 and the inclusion of medication in the treatment plan. A forthcoming complex ADHD guideline
1646 from the SDBP will provide additional information on diagnostic evaluation and treatment of
1647 children and adolescents with ADHD treatment failure and/or ADHD that is complicated by
1648 coexisting developmental or mental health conditions.

1649
1650 Treatment failure could result from poor adherence to the treatment plan. Increased
1651 monitoring and education, especially by including the patient, may increase adherence. It is
1652 helpful to try to identify the issues restricting adherence, including lack of information about, or
1653 understanding of, the treatment plan. It is also important to recognize that cultural factors may
1654 impact the patient’s treatment and outcomes.


1655
1656 If the child continues to struggle despite the school’s interventions and treatment for
1657 ADHD, further psychoeducational, neuropsychological, and/or language assessments are
1658 necessary to evaluate for a learning, language, or processing disorder. The clinician may
1659 recommend evaluation by an independent psychologist or neuropsychologist.

1660
1661

1662 **VII. CHILDREN AND ADOLESCENTS FOR WHOM AN ADHD DIAGNOSIS IS NOT
1663 MADE**

1664

1665



1666

1667

1668 If the evaluation identifies or suggests another disorder is the cause of the concerning
1669 signs and symptoms, it is appropriate to exit this algorithm.

1670

1671 **VII a. Other Condition**

1672

1673 The subsequent approach is dictated by the evaluation's results. If the PCC has the
1674 expertise and ability to evaluate and treat the other or comorbid condition, he or she may do so.
1675 Many collaborative care models exist to help facilitate a pediatrician's comfort with comorbidity,
1676 as well as programs that teach pediatricians to manage comorbidities. It is important for the PCC
1677 to frame the referral questions clearly, if a referral is made. A co-management plan must be
1678 established that addresses the families' and child/adolescent's ongoing needs for education and
1679 general and specialty health care. Resources from the AAP Mental Health Initiatives and the
1680 forthcoming complex ADHD clinical practice guideline from the SDBP may be helpful.^{4,46,112}

1681

1682 **VII b. Apparently Typical or Developmental Variation**

1683

Evaluation may show that the child or adolescent's inattention, activity level, and impulsivity are within the typical range of development; mildly or inconsistently elevated in comparison to his or her peers; or is not associated with any functional impairment in behavior, academics, social skills, or other domains. The clinician can probe further to determine whether the parents' concerns are attributable to other issues in the family, such as parental tension or drug use by a family member; whether they are caused by other issues in school, such as social pressures or bullying; or whether they are within the spectrum of typical development.

In talking with parents, it may help to explain that ADHD differs from a condition like pregnancy, which is a “yes” or “no” condition. With ADHD, behaviors follow a spectrum from variations on typical behavior to atypical behaviors that cause problems but are not severe enough to be considered a disorder, to consistent behaviors that are severe enough to be considered a disorder. With problematic behaviors, it is helpful for the PCC to provide education about both the range of typical development and strategies to improve the child or adolescent’s behaviors. A schedule of enhanced surveillance absolves the family of the need to reinitiate contact if the situation deteriorates. If a recommendation for continued routine systematic surveillance is made by the PCC, it is important to provide reassurance that ongoing concerns can be revisited in at future primary care visits.

VII c. Children and Adolescents With Inattention or Hyperactivity/Impulsivity (Problem Level)

Children and adolescents whose symptoms do not meet the criteria for diagnosis of ADHD may still encounter some difficulties or mild impairment in some settings, as described in the *Diagnostic and Statistical Manual for Primary Care (DSM-PC), Child and Adolescent Version*.¹¹³ For these patients, enhanced surveillance is recommended. PCCs are encouraged to provide education for both the patient and his or her family, specifically about triggers for inattention and/or hyperactivity as well as behavior-management strategies.

Medication is not appropriate for children/adolescents whose symptoms do not meet *DSM-5* criteria for diagnosis of ADHD, but PTBM does not require a diagnosis of ADHD to be recommended.

VIII. COMPLEMENTARY AND ALTERNATIVE THERAPIES/INTEGRATIVE MEDICINE

Families of children and adolescents with ADHD increasingly ask their pediatrician and other PCCs about complementary and alternative therapies. These include megavitamins and other dietary alterations, vision/visual training, chelation, EEG biofeedback, and working memory (eg, cognitive training) programs.¹¹⁴ As noted, there is insufficient evidence to suggest that these therapies lead to changes in ADHD's core symptoms or function. For many complementary and alternative therapies, limited information is available about their safety. Both chelation and megavitamins have been proven to cause adverse effects and are contraindicated.^{115,116} For these reasons, complementary and alternative therapies are not recommended.

Pediatricians and other PCCs can play a constructive role in helping families make thoughtful treatment choices by reviewing the goals and/or effects claimed for a given treatment,

1732 the state of evidence to support or discourage use of the treatment, and known or potential
1733 adverse effects. If families are interested in trying complementary and alternative treatments, it is
1734 helpful to have them define specific measurable goals to monitor the treatment's impact.
1735 Families also need to be strongly encouraged to use evidence-based interventions while they
1736 explore complementary and alternative treatments. PCCs have to respect families' interests and
1737 preferences while they address and answer questions about complementary and alternative
1738 therapies.

1739
1740 Pediatricians and other PCCs should ask about additional therapies that families may be
1741 administering to adequately monitor for drug interactions. Parents and children or adolescents
1742 who do not feel that their choices in health care are respected by their PCCs may be less likely to
1743 communicate about complementary or alternative therapies/integrative medicine.

1744 1745 **IX. IMPLEMENTATION ISSUES: PREPARING THE PRACTICE**

1746
1747 Implementation of the process described in this algorithm can be enhanced with
1748 preparation of the practice to meet the needs of children and adolescents with ADHD. This
1749 preparation includes both internal practice characteristics and relationships within the
1750 community. (More detail can be found in the [AAP Mental Health Initiatives](#)' resources.^{4,117})

1751
1752 The following office procedures and resources will help practices facilitate the steps in
1753 this algorithm:

- 1754 • Developing a packet of ADHD questionnaires and rating scales for parents and teachers to
1755 complete before a scheduled visit.
- 1756 • Allotting adequate time for ADHD-related visits.
- 1757 • Determining billing and documentation procedures and monitoring insurance payments to
1758 appropriately capture the services rendered to the extent possible.
- 1759 • Implementing methods to track and follow patients (see supplemental paper "Systemic
1760 Barriers to the Care of Children and Adolescents with ADHD" for more information on this
1761 issue).
- 1762 • Asking questions during clinical encounters and promoting patient education materials (ie,
1763 brochures and posters) alerting parents and patients that problem behaviors, school problems,
1764 and ADHD are appropriate issues to discuss with the PCC.
- 1765 • Developing an office system for monitoring and titrating medication, including
1766 communication with parents and teachers. For stimulant medications—which are controlled
1767 substances requiring new, monthly prescriptions—it is necessary to develop a monitoring and
1768 refill process including periodic review of the state's database of controlled substance
1769 prescriptions. (Any such system is based on the PCC's assessment of family organization,
1770 phone access, and parent-teacher communication effectiveness.)
- 1771 • Using the ADHD Toolkit resources.

1772
1773 Establishing relations with schools and other agencies can facilitate communication and
1774 establish clear expectations when collaborating on care for a child. A community-level system
1775 that reflects consensus among district school staff and local PCCs for key elements of diagnosis,
1776 interventions, and ongoing communication can help to provide consistent, well-coordinated, and
1777 cost-effective care. A community-based system with schools relieves the individual PCC from
1778 negotiating with each school about care and communication regarding each patient. Offices that

1779 have incorporated medical home principles are ideal for establishing this kind of community-
1780 level system. Although achieving the level of coordination described below is ideal and takes
1781 consistent effort over the years—especially in areas with multiple separate school systems—
1782 some aspects may be achieved relatively quickly and will enhance services for children.

1783

1784 The key elements for a community-based collaborative system include consensus on:

1785 • A clear and organized process by which an evaluation can be initiated when concerns are
1786 identified either by parents or school personnel;

1787 • A packet of information completed by parents and teachers about each child/adolescent
1788 referred to the PCC;

1789 • A contact person at the practice to receive information from parents and teachers at the time
1790 of evaluation and during follow-up;

1791 • An assessment process to investigate coexisting conditions;

1792 • A directory of evidence-based interventions available in the community;

1793 • An ongoing process for follow-up visits, phone calls, teacher reports, and medication refills;

1794 • Availability of forms for collecting and exchanging information;

1795 • A plan for keeping school staff and PCCs up to date on the process; and

1796 • Awareness of the network of mental health providers in your area and establishments of
1797 collaborative relationships with them.

1798

1799 The PCC may face challenges to developing such a collaborative process. For example, a
1800 PCC is typically caring for children from more than one school system, a school system may be
1801 large and not easily accessed, schools may have limited staff and resources to complete
1802 assessments, or scheduling may make it difficult for the PCC to communicate with school
1803 personnel. Further complicating these efforts is the fact that many providers encounter a lack of
1804 recognition and payment for the time involved in coordinating care. These barriers may hamper
1805 efforts to provide the internal resources within a practice and coordination across schools and
1806 other providers that are described above; nevertheless, some pediatricians and other PCCs have
1807 found ways to lessen some of these obstacles (see supplemental paper “Systemic Barriers to the
1808 Care of Children and Adolescents with ADHD” for more information on overcoming
1809 challenges).

1810

1811 In the case of multiple or large school systems in a community, the PCC may want to begin
1812 with 1 school psychologist or principal, or several practices can initiate contact collectively with
1813 a community school system. Agreement among the clinicians on the components of a good
1814 evaluation process facilitates cooperation and communication with the school toward common
1815 goals. Agreement on behavior rating scales used can facilitate completion by school personnel.
1816 Standard communication forms that monitor progress and specific interventions can be
1817 exchanged among the school and the pediatric office to share information. Collaborative systems
1818 can extend to other providers, who may comanage care with a PCC. Such providers may include
1819 a mental health professional who sees the child or adolescent for psychosocial interventions, or a
1820 specialist to address difficult cases, such as a developmental-behavioral pediatrician, child and
1821 adolescent psychiatrist, child neurologist, neurodevelopmental disability physician, or
1822 psychologist. The AAP Mental Health Initiatives provides a full discussion of collaborative
1823 relationships with mental health professionals, including colocation and integrated models, in its
1824 Chapter Action Kit and PediaLink Module.^{4,118}

1825

1826 Achieving this infrastructure in the practice and the coordination across schools and other
1827 providers will enhance the PCC's ability to implement the treatment guidelines and this
1828 algorithm. Achieving these ideals is not necessary for providing care consistent with these
1829 practices, however.

1830

1831 **X. CONCLUSION**

1832

1833 ADHD is the most common neurobiological disorder of children/adolescents. Untreated
1834 or undertreated ADHD can have far-reaching and serious consequences for the child or
1835 adolescent's health and well-being. Fortunately, effective treatments are available, as are
1836 methods for assessing and diagnosing ADHD in children/adolescents. The AAP is committed to
1837 supporting primary care physicians in providing quality care to children/adolescents with ADHD
1838 and their families. This algorithm represents a portion of that commitment and an effort to assist
1839 pediatricians and other PCCs to deliver care that meets the quality goals of the practice guideline.
1840 This paper, in combination with the guideline and barriers supplemental paper, is intended to
1841 provide support and guidance in what is currently the best evidence-based care for their patients
1842 with ADHD. Additional support and guidance can be obtained through the work and publications
1843 of the AAP Mental Health Initiatives.^{4,112}

1844

1845 **ABBREVIATIONS:**

- 1846 • AAP, American Academy of Pediatrics
- 1847 • ADHD, attention-deficit/hyperactivity disorder
- 1848 • ADHD/I, ADHD primarily of the inattentive presentation
- 1849 • ADHD/HI, ADHD primarily of the hyperactive-impulsive presentation
- 1850 • ADHD/C, ADHD of the combined presentation
- 1851 • CBT, Cognitive Behavioral Therapy
- 1852 • CHADD, Children and Adults with Attention-Deficit/Hyperactivity Disorder
- 1853 • *DSM-5, Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition*
- 1854 • EEG, electroencephalography
- 1855 • FDA, US Food and Drug Administration
- 1856 • IDEA, Individuals with Disability Education Act
- 1857 • MTA, Multimodal Therapy of ADHD
- 1858 • OSAS, obstructive sleep apnea syndrome
- 1859 • PTBM, Parent Training in Behavior Management
- 1860 • PCC, primary care clinician
- 1861 • RLS/PLMD, restless legs syndrome/periodic limb movement disorder
- 1862 • SDBP, Society for Developmental and Behavioral Pediatrics

1865 **REFERENCES**

1866

1867 1. Jane Meschan Foy (Editor), *Algorithm: A Process for Integrating Mental Health Care*
1868 *into Pediatric Practice, in Mental Health Care of Children and Adolescents: A Guide for*
1869 *Primary Care Clinicians*, AAP 2018, p. 815. See also: <https://www.aap.org/en-us/advocacy-and-policy/aap-health-initiatives/Mental-Health/Pages/default.aspx>

1870 2. <https://brightfutures.aap.org/Pages/default.aspx>

1871 3. American Academy of Pediatrics, Task Force on Mental Health. Addressing Mental
1872 Health Concerns in Primary Care: A Clinician's Toolkit [CD-ROM]. Elk Grove Village,
1873 IL: American Academy of Pediatrics; 2010.

1874 4. American Academy of Pediatrics, Mental Health Initiatives: <https://www.aap.org/en-us/advocacy-and-policy/aap-health-initiatives/Mental-Health/Pages/default.aspx>

1875 5. Tina L. Cheng, Mickey A. Emmanuel, Daniel J. Levy, Renee R. Jenkins, "Child Health
1876 Disparities: What Can a Clinician Do?" *Pediatrics* 2015; 136(5): 961-968.

1877 6. AAP Diversity and Inclusion Statement; *Pediatrics* Apr 2018, 141 (4) e20180193; DOI:
1878 10.1542/peds.2018-0193

1879 7. Fernando Stein, Karen Remley, Danielle Laraque-Arena, DeWayne M. Pursley, "New
1880 Resources and Strategies to Advance the AAP's Values of Diversity, Inclusion, and
1881 Health Equity;" *Pediatrics* 2018; 141(4) e20180177; DOI: 10.1542/peds.2018-0177

1882 8. AAP COMMITTEE ON PEDIATRIC WORKFORCE; "Enhancing Pediatric Workforce
1883 Diversity and Providing Culturally Effective Pediatric Care: Implications for Practice,
1884 Education, and Policy Making," *Pediatrics* 2013; 32 (4) e1105-e1116; DOI:
1885 10.1542/peds.2013-2268

1886 9. Rachel Stein Berman, Milani R. Patel, Peter F. Belamarich, Rachel S. Gross; "Screening
1887 for Poverty and Poverty-Related Social Determinants of Health;" *Pediatrics in Review*
1888 2018; 39 (5) 235-246; DOI: 10.1542/pir.2017-0123

1889 10. Chronis AM, Lahey BB, Pelham WE Jr, Kipp HL, Baumann BL, Lee SS.
1890 Psychopathology and substance use in parents of young children with attention-
1891 deficit/hyperactivity disorder. *J Am Acad Child Adolesc Psychiatry*. 2003;42(12):1424-
1892 1432.

1893 11. "Iterative Mental Health Assessment," and "Appendix 2: Mental Health Tools for
1894 Pediatrics," *Mental Health Care of Children and Adolescents: A Guide for Primary Care*
1895 *Clinicians*, Jane Meschan Foy (Editor), Itasca (IL): American Academy of Pediatrics,
1896 2018.

1897 12. Wolraich, ML, Bard D, Neas, B, Doffing M, Beck, L. "The Psychometric Properties of
1898 the Vanderbilt ADHD Diagnostic Teacher Rating Scale in a Community Population,"
1899 *Journal of Developmental and Behavioral Pediatrics*, 2013 34(2): 83-93.

1900 13. DuPaul, G.J., Power, T.J., Anastopoulos, A.D. & Reid, R. ADHD Rating Scale – 5 for
1901 Children and Adolescents. New York, NY: Guilford Press, 2016.

1902 14. Bard, D., Wolraich, M.L., Neas, B., Doffing M., Beck, L. "The Psychometric Properties
1903 of the Vanderbilt ADHD Diagnostic Parent Rating Scale in a Community Population,"
1904 *Journal of Developmental and Behavioral Pediatrics*, 2013; 34(2): 72-82.

1905 15. Goodman R. "The extended version of the Strengths and Difficulties Questionnaire as a
1906 guide to child psychiatric caseness and consequent burden," *J Child Psychol Psychiatry*,
1907 1999; 40(5): 791-801.

1908 16. Shaffer D, Gould MS, Brasic J, et al. "A children's global assessment scale (CGAS),"
1909 *Arch Gen Psychiatry*, 1983; 40(11):1228-1231.

1910 17. Brown R, Freeman WS, Perrin JM, et al. "Prevalence and assessment of attention-
1911

1913 18. deficit/hyperactivity disorder in primary care settings," *Pediatrics*, 2001; 107(3):e43.

1914 19. Evans, S.W., Allen, J., Moore, S., & Strauss, V. "Measuring symptoms and functioning of youth with ADHD in middle schools," *Journal of Abnormal Child Psychology*, 2005; 33, 695-706.

1915 19. Wolraich ML, Lambert EW, Bickman L, Simmons T, Doffing MA, Worley KA.

1916 19. "Assessing the impact of parent and teacher agreement on diagnosing ADHD," *J Dev Behav Pediatr*. 2004;25(1):41-47.

1917 20. DiPerna, J.C. & Elliott, S.N. Academic Competence Evaluation Scales (ACES). San Antonio, TX: The Psychological Corporation, 2000.

1918 21. Smith, B.H., Pelham, W.E., Gnagy, E., Molina, B., & Evans, S.W. "The reliability, validity, and unique contributions of self-report by adolescents receiving treatment for Attention-Deficit Hyperactivity Disorder," *Journal of Consulting and Clinical Psychology*, 2000; 68: 489-499.

1919 22. Horza B, Pelham WE, Dobbs J, Owens JS, Pillow DR "Do Boys with Attention-Deficit/Hyperactivity Disorder Have Positive Illusory Self-concepts?" *Journal of Abnormal Psychology*, 2002 111: 268-278.

1920 23. Zuckerbrot R, Cheung AH, Jensen PS, Stein RE, Laraque D, "GLAD-PC Steering Group. Guidelines for Adolescent Depression in Primary Care (GLAD-PC): I. Identification, assessment, and initial patsmanagement," *Pediatrics*, 2007; 120(5):e1299-e1312.

1921 24. Cheung A, Zuckerbrot RA, Jensen PS, Ghalib K, Laraque D, Stein RE, "GLAD-PC Steering Group. Guidelines for Adolescent Depression in Primary Care (GLAD-PC): II. Treatment and ongoing management," *Pediatrics*, 2007;120(5):e1313-e1326.

1922 25. "Low Mood," and "Appendix 2: Mental Health Tools for Pediatrics," *Mental Health Care of Children and Adolescents: A Guide for Primary Care Clinicians*, Jane Meschan Foy (Editor), Itasca (IL): American Academy of Pediatrics, 2018.

1923 26. The Center for Adolescent Substance Use Research, Children's Hospital Boston. CRAFFT: Screening Adolescents for Alcohol and Drugs. Boston, MA: Children's Hospital Boston; 2001. Available at:
<http://www.childrenshospital.org/views/february09/images/CRAFFT.pdf>.

1924 27. Levy S, Weiss R, Sherritt L, Ziemnik R, Spalding A, VanHook S, Shrier LA, "An electronic screen for triaging adolescent substance use by risk levels," *JAMA Pediatrics*, 2014; 168(9):822-828. Available at <https://www.druguse.gov/ast/s2bi/#/>.

1925 28. The "SCREEN for CHILD ANXIETY RELATED EMOTIONAL DISORDERS" (SCARED) is available from the University of Pittsburgh:
<https://www.pediatricbipolar.pitt.edu/resources/instruments>.

1926 29. Kovacs M, *Children's Depression Inventory, Second Edition™ (CDI-2®)*, North Tonawanda (NY): MHS Assessments, 2018. Available online at:
<https://www.mhs.com/MHS-Assessment?prodname=cdi2>.

1927 30. Richardson LP, McCauley E, Grossman DC, McCarty CA, Richards J, Russo JE, Rockhill C, Katon W, "Evaluation of the Patient Health Questionnaire-9 Item for Detecting Major Depression Among Adolescents," *Pediatrics*, 2010; 126(6): 1117-23. doi: 10.1542/peds.2010-0852. Epub 2010 Nov 1.

1928 31. Sleator EK, Ullman RK, "Can the physician diagnose hyperactivity in the office?" *Pediatrics*, 1981; 67(1):13-17.

1929 32. American Academy of Pediatrics, Fetal Alcohol Spectrum Disorders Program:
<https://www.aap.org/en-us/advocacy-and-policy/aap-health-initiatives/fetal-alcohol-spectrum-disorders-toolkit/Pages/default.aspx>.

1930 33. Hagan JF, Balachova T, Bertrand J, et al. Neurobehavioral Disorder Associated With

2009 5(2): 274-282.

2010 51. Cortese S, Konofal E, Lecendreux M, et al., "Restless legs syndrome and attention-deficit/hyperactivity disorder: a review of the literature," *Sleep*, 2005; 28(8): 1007-1013.

2011 52. Weiss MD, Wasdell MB, Bomben MM, Rea KJ, Freeman RD, "Sleep hygiene and melatonin treatment for children and adolescents with ADHD and initial insomnia," *J Am Acad Child Adolesc Psychiatry*. 2006; 45(5): 512-519.

2012 53. Stein MA, Sarampote CS, Waldman ID, et al., "A Dose-Response Study of OROS Methylphenidate in Children and Adolescents with ADHD," *Pediatrics*, 2003; 112(5): e404.

2013 54. Corkum P, Panton R, Ironside S, Macpherson M, Williams T, "Acute impact of immediate release methylphenidate administered three times a day on sleep in children with attention-deficit/hyperactivity disorder," *J Pediatr Psychol*, 2008; 33(4): 368-379.

2014 55. O'Brien LM, Ivanenko A, Crabtree VM, et al., "The effect of stimulants on sleep characteristics in children with attention deficit/hyperactivity disorder," *Sleep Med*, 2003; 4(4): 309-316.

2015 56. Owens J, Sangal RB, Sutton VK, Bakken R, Allen AJ, Kelsey D, "Subjective and objective measures of sleep in children with attention-deficit/hyperactivity disorder," *Sleep Med*. 2009; 10(4): 446-456.

2016 57. Owens JA, "A clinical overview of sleep and attention-deficit/hyperactivity disorder in children and adolescents," *J Can Acad Child Adolesc Psychiatry*, 2009; 18(2): 92-102.

2017 58. Mick E, Biederman J, Jetton J, Faraone SV, "Sleep disturbances associated with ADHD: the impact of psychiatric comorbidity and pharmacotherapy," *J Child Adolesc Psychopharmacol*, 2000; 10(3): 223-231.

2018 59. van der Heijden KB, Smits MG, van Someren EJ, Boudewijn Gunning W, "Prediction of melatonin efficacy by pretreatment dim light melatonin onset in children with idiopathic chronic sleep onset insomnia," *J Sleep Res*, 2005; 14(2): 187-194.

2019 60. Cortese S, Faraone S, Konofal E, Lecendreux M, "Sleep in children with attention-deficit/hyperactivity disorder: meta-analysis of subjective and objective studies," *J Am Acad Child Adolesc Psychiatry*. 2009; 48(9): 894-908.

2020 61. Golan N, Shahar E, Ravid S, Pillar G, "Sleep disorders and daytime sleepiness in children with attention-deficit/hyperactive disorder," *Sleep*, 2004; 27(2): 261-266.

2021 62. Lecendreux M, Konofal E, Bouvard M, Falissard B, Mouren-Simeoni MC, "Sleep and alertness in children with ADHD," *J Child Psychol Psychiatry*, 2000; 41(6): 803-812.

2022 63. Owens J, Dalzell V, "Use of the 'BEARS' sleep screening tool in a pediatric residents' continuity clinic: a pilot study," *Sleep Med*. 2005; 6(1): 63-69.

2023 64. Chervin RD, Hedger K, Dillon JE, Pituch KJ, "Pediatric sleep questionnaire (PSQ): validity and reliability of scales for sleep-disordered breathing, snoring, sleepiness, and behavioral problems," *Sleep Med*. 2000; 1(1): 21-32.

2024 65. Owens J, Nobile C, McGuinn M, Spirito A, "The Children's Sleep Habits Questionnaire: construction and validation of a sleep survey for school-aged children," *Sleep*, 2000; 23(8): 1043-1051.

2025 66. Aurora RN, Zak RS, Karippot A, Lamm CI, Morgenthaler TI, Auerbach SH, Bista SR, Casey KR, Chowdhuri S, Kristo DA, Ramar K, "Practice parameters for the respiratory indications for polysomnography in children," *Sleep*, 2011; 34(3): 379-88.
<https://www.ncbi.nlm.nih.gov/pubmed/21359087>

2026 67. Aurora RN, Lamm, CI, Zak RS, Kristo DA, Bista SR, Rowley JA, Casey KR, "Practice parameters for the non-respiratory indications for polysomnography and multiple sleep latency testing for children," *Sleep*, 2012; 35(11): 1467-73.

2057 68. <https://www.ncbi.nlm.nih.gov/pubmed/23115395>
2058 68. Gruber R, Wiebe S, Montecalvo L, Brunetti B, Amsel R, Carrier J, "Impact of sleep
2059 restriction on neurobehavioral functioning of children with attention-deficit hyperactivity
2060 disorder," *Sleep*, 2011; 34(3): 315-323.
2061 69. Bunford, N., Evans, S.W. & Wymbs, F, "ADHD and emotion dysregulation among
2062 children and adolescents," *Clinical Child and Family Psychology Review*, 2015; 18: 185-
2063 217.
2064 70. Joshua M. Langberg, Aaron J. Vaughn, William B. Brinkman, Tanya Froehlich and
2065 Jeffery N. Epstein, "Clinical Utility of the Vanderbilt ADHD Rating Scale for Ruling Out
2066 Comorbid Learning Disorders," *Pediatrics* 2010; 126(5): e1033-e1038. DOI:
2067 10.1542/peds.2010-1267
2068 71. Extending the Medical Home to Meet Your Patients' Mental Health Needs: Is Telehealth
2069 the Answer?; Susan J. Kressly; *Pediatrics* Mar 2019, 143 (3) e20183765; DOI:
2070 10.1542/peds.2018-3765
2071 72. Emily Dudek, Elizabeth Henschen, Elonna Finkle, Shrinal Vyas, Dana Fiszbein, Archana
2072 Shukla, Improving Continuity in a Patient Centered Medical Home; *Pediatrics* May 2018,
2073 142 (1 MeetingAbstract) 366; DOI: 10.1542/peds.142.1_MeetingAbstract.366
2074 73. Children with Developmental, Behavioral, or Emotional Problems Are Less Likely to
2075 Have a Medical Home; Almaz S. Dessie, Priyadarshini Hirway, Annie Gjelsvik;
2076 *Pediatrics* Jan 2018, 141 (1 MeetingAbstract) 23; DOI:
2077 10.1542/peds.141.1_MeetingAbstract.23
2078 74. Jane Meschan Foy, The Medical Home and Integrated Behavioral Health; *Pediatrics* May
2079 2015, 135 (5) 930-931; DOI: 10.1542/peds.2015-0748
2080 75. The Medical Home and Integrated Behavioral Health: Advancing the Policy Agenda;
2081 Jeremy Ader, Christopher J. Stille, David Keller, Benjamin F. Miller, Michael S. Barr,
2082 James M. Perrin; *Pediatrics* May 2015, 135 (5) 909-917; DOI: 10.1542/peds.2014-3941
2083 76. American Academy of Pediatrics, "Collaboration in Practice: Implementing TeamBased
2084 Care," *Pediatrics* 2016;138(2):e20161486. DOI: 10.1542/peds.2016-1486
2085 77. Kressley, Susan, "Team-based care for children: Who should be included and who should
2086 lead?," *AAP News*, July 24, 2017. Online:
2087 <https://www.aappublications.org/news/2017/07/24/TeamBased072417>
2088 78. Katkin JP, Kressly SJ, Edwards AR, et al. Guiding Principles for Team-Based Pediatric
2089 Care. *Pediatrics*. 2017; 140(2):e20171489
2090 79. Godoy L, Hodgkinson S, Robertson HA, et al. Increasing Mental Health Engagement
2091 From Primary Care: The Potential Role of Family Navigation. *Pediatrics*.
2092 2019;143(4):e20182418
2093 80. Mark L. Wolraich and Joseph F. Hagan, Jr, ADHD: What Every Parent Needs to Know
2094 (3rd Edition), Itasca (IL): American Academy of Pediatrics, 2019. Online at:
2095 <https://shop.aap.org/adhd-paperback/>
2096 81. American Academy of Pediatrics (AAP), Understanding ADHD, Itasca (IL): AAP, 2017.
2097 Online: <https://shop.aap.org/understanding-adhd-brochure-50pk-brochure/>
2098 82. HealthyChildren.org, *Health Issues: ADHD*, Itasca (IL): American Academy of
2099 Pediatrics, 2018. Online: <https://www.healthychildren.org/English/health-issues/conditions/adhd/Pages/default.aspx>
2100 83. American Academy of Pediatrics, ADHD Provider Toolkit (3rd Edition), in production.
2101 84. Reiff M. *ADHD: What Every Parent Needs to Know*. 2nd ed. Elk Grove Village, IL:
2102 American Academy of Pediatrics, 2011.
2103 85. Charach A, Fernandez R, "Enhancing ADHD Medication Adherence: Challenges and

2105 Opportunities," *Current Psychiatry Reports*, 2013; 15(7): 371. doi:10.1007/s11920-013-0371-6.

2106 86. Chang Z, Quinn PD, Hur K, Gibbons RD, Sjolander A, Larsson H, D'Onofrio BM,
2107 "Association Between Medication Use for Attention-Deficit/Hyperactivity Disorder and
2108 Risk of Motor Vehicle Crashes," *JAMA Psychiatry*, 2017.
2109 doi:10.1001/jamapsychiatry.2017.0659

2110 87. Cortese, S., Adamo, N., Del Giovane, C., Mohr-Jensen, C., Hayes, AJ, Carucci, S, et al.,
2111 "Comparative efficacy and tolerability of medications for attention-deficit hyperactivity
2112 disorder in children, adolescents, and adults: a systematic review and network meta-
2113 analysis," *Lancet* 2018; 5(9): P727-738. DOI:[https://doi.org/10.1016/S2215-0366\(18\)30269-4](https://doi.org/10.1016/S2215-0366(18)30269-4)

2114 88. Pozzi M, Carnovale C, Peeters GGAM, Gentili M, Antoniazzi S, Radice S, Clementi E,
2115 Nobile M, "Adverse drug events related to mood and emotion in paediatric patients
2116 treated for ADHD: A meta-analysis," *J Affective Disorders*, 2018; 238: 161-178. DOI:
2117 [10.1016/j.jad.2018.05.021](https://doi.org/10.1016/j.jad.2018.05.021)

2118 89. Greenhill LL, Abikoff HB, Arnold E, et al., "Medication treatment strategies in the MTA
2119 study: Relevance to clinicians and researchers," *J Am Acad Child Adolesc Psychiatry*.
2120 1996; 34(10): 1304-1313.

2121 90. Molina BS, Hinshaw SP, Swanson JM, et al. The MTA at 8 years: prospective follow-up
2122 of children treated for combined type ADHD in the multisite study," *J Am Acad Child
2123 Adolesc Psychiatry*. 2009; 48(5): 484-500.

2124 91. Evans, S.W., Owens, J.S., Wymbs, B.T. & Ray, A.R. "Evidence-based psychosocial
2125 treatments for children and adolescents with attention-deficit/hyperactivity disorder,"
2126 *Journal of Clinical Child and Adolescent Psychology*, 2018; 47: 157-198.

2127 92. Robin, A. L., & Foster, S. L. *Negotiating Parent Adolescent Conflict: A Behavioral-
2128 Family Systems Approach*. New York, NY: The Guilford Press, 1989.

2129 93. Barkley, R. A., Edwards, G., Laneri, M., Fletcher, K., & Metevia, L., "The efficacy of
2130 problem-solving communication training alone, behavior management training alone, and
2131 their combination for parent-adolescent conflict in teenagers with ADHD and ODD."
2132 *Journal of Consulting and Clinical Psychology*, 2001; 69(6): 926-941.

2133 94. Sibley, M. H., Graziano, P. A., Kuriyan, A. B., Coxe, S., Pelham, W. E., Rodriguez, L...
2134 "Ward, A. (2016). Parent-teen behavior therapy + motivational interviewing for
2135 adolescents with ADHD," *Journal of Consulting and Clinical Psychology*, 2016; 84(8):
2136 699-712.

2137 95. Bloch MH, Qawasmi A, "Omega-3 fatty acid supplementation for the treatment of
2138 children with attention-deficit/hyperactivity disorder symptomatology: systematic review
2139 and meta-analysis," *J Am Acad Child Adolesc Psychiatry*, 2011;50(10):991-1000. doi:
2140 10.1016/j.jaac.2011.06.008. Epub 2011 Aug 12. Review. PMID: 21961774.

2141 96. Understood.org, LLC: <https://www.understood.org/en>

2142 97. Impact ADHD: <https://impactadhd.com/resources/free-impactadhd-resources-for-parents/>

2143 98. Impact ADHD: <https://www.youtube.com/user/ImpactADHD>

2144 99. Evans, S.W., Langberg, J.M., Schultz, B.K., Vaughn, A., Altaye, M., Marshall, S.A. &
2145 Zoromski, A.K., (2016). Evaluation of a school-based treatment program for young
2146 adolescents with ADHD. *Journal of Consulting and Clinical Psychology*, 84, 15-30.

2147 100. Schultz, B.K., Evans, S.W., Langberg, J.M. & Schoemann, A.M. (2017). Outcomes for
2148 adolescents who comply with long-term psychosocial treatment for ADHD. *Journal of
2149 Consulting and Clinical Psychology*, 85, 250-261.

2150 101. Davila RR, Williams ML, MacDonald JT, "Memorandum on clarification of policy to

2153 address the needs of children with attention deficit disorders within general and/or special
2154 education," In: Parker HC, (Ed.), *The ADD Hyperactivity Handbook for Schools*.
2155 Plantation, FL: Impact Publications Inc; 1991: 261-268.

2156 102. Halfon N, Forrest CB, Lerner RM, Faustman EM, *Handbook of Life Course Health
2157 Development*, Cham, Switzerland: Springer 2018, 2018.

2158 103. Evans, S. W., Owens, J. S., Mautone, J. A., DuPaul, G. J., & Power, T. J, "Toward a
2159 comprehensive, Life Course Model of care for youth with ADHD," In M. Weist, N.
2160 Lever, C. Bradshaw, & J. Owens (Eds.), *Handbook of School Mental Health (2nd edition)*,
2161 New York, NY: Springer, 2014, pages 413-426.

2162 104. Pfiffner LJ, Hinshaw, S. P., Owens, E. B., Zalecki, C. A., Kaiser, N. M., Villodas, M., &
2163 McBurnett, K. "A two-site randomized clinical trial of integrated psychosocial treatment
2164 for ADHD-inattentive type," *Journal of Consulting and Clinical Psychology*, 2014;
2165 82(6): 1115-1127.

2166 105. angberg, J. M., Dvorsky, M. R., Molitor, S. J., Bourchtein, E., Eddy, L. D., Smith, Z.
2167 R.,...Eadeh, H. "Overcoming the research-to-practice gap: A randomized trial with two
2168 brief homework and organization interventions for students with ADHD as implemented
2169 by school mental health providers," *Journal of Consulting and Clinical Psychology*,
2170 2018; 86(1): 39-55.

2171 106. Newcorn J, Kratochvil CJ, Allen AJ, et al., "Atomoxetine and osmotically released
2172 methylphenidate for the treatment of attention deficit hyperactivity disorder: acute
2173 comparison and differential response," *Am J Psychiatry*, 2008; 165(6): 721-730.

2174 107. Greenhill L, Kollins S, Abikoff H, McCracken J, Riddle M, Swanson J, "Efficacy and
2175 safety of immediate-release methylphenidate treatment for preschoolers with ADHD," *J
2176 Am Acad Child Adolesc Psychiatry*, 2006; 45(11): 1284-1293.

2177 108. Visser SN, Lesesne CA, Perou R, "National estimates and factors associated with
2178 medication treatment for childhood attention-deficit/hyperactivity disorder," *Pediatrics*,
2179 2007; 119(Suppl 1): S99-S106.

2180 109. Kratochvil CJ, Vaughan VS, Stoner JA, et al., "A double-blind-placebo controlled study
2181 of atomoxetine in young children with ADHD," *Pediatrics*, 2011; 127(4): e-862.

2182 110. Charach A, Volpe T, Boydell KM, Gearing RE, "A theoretical approach to medication
2183 adherence for children and youth with psychiatric disorders," *Harv Rev Psychiatry*, 2008;
2184 16(2): 126-135.

2185 111. Wilens TE, Adler LA, Adams J, Sgambati S, Rotrosen J, Sawtelle R, Utzinger L, Fusillo
2186 S, "Misuse and Diversion of Stimulants Prescribed for ADHD: A Systematic Review of
2187 the Literature," *Journal of the American Academy of Child & Adolescent Psychiatry*,
2188 2008; 47(1): 21-31. doi: 10.1097/chi.0b013e31815a56f1.

2189 112. *Mental Health Care of Children and Adolescents: A Guide for Primary Care Clinicians*,
2190 Jane Meschan Foy (Editor), Itasca (IL): American Academy of Pediatrics, 2018.

2191 113. Wolraich ML, Felice ME, Drotar DD. *The Classification of Child and Adolescent Mental
2192 Conditions in Primary Care: Diagnostic and Statistical Manual for Primary Care (DSM-
2193 PC), Child and Adolescent Version*. Elk Grove, IL: American Academy of Pediatrics,
2194 1996.

2195 114. Chan E, "Complementary and alternative medicine in developmental-behavioral
2196 pediatrics," In: Wolraich ML, Drotar DD, Dworkin PH, Perrin EC, (Eds.),
2197 *Developmental-Behavioral Pediatrics: Evidence and Practice*. Philadelphia, PA: Mosby
2198 Elsevier, 2008, pages 259-280.

2199 115. Chan E, "The role of complementary and alternative medicine in attention-deficit
2200 hyperactivity disorder," *J Dev Behav Pediatr*, 2002; 23(1 Suppl): S37-45. PMID:

2201 11875289.

2202 116. James S, Williams K, Silove N, Stevenson SW, “Chelation for autism spectrum disorder
2203 (ASD),” *Cochrane Database of Systematic Reviews*, 2013, Issue 10. Art. No.: CD010766.
2204 DOI: 10.1002/14651858.CD010766.

2205 117. “Office and Network Systems to Support Mental Health Care,” in *Mental Health Care of
2206 Children and Adolescents: A Guide for Primary Care Clinicians*, Jane Meschan Foy
2207 (Editor), Itasca (IL), American Academy of Pediatrics, 2018.

2208 118. *Mental Health Care of Children and Adolescents: A Guide for Primary Care Clinicians*,
2209 Jane Meschan Foy, Editor, AAP 2018, p. 815. See also: <https://www.aap.org/en-us/advocacy-and-policy/aap-health-initiatives/Mental-Health/Pages/default.aspx>
2211